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In Western Europe and North America, acute myeloid leukaemia (AML) is 
predominantly a disease of the elderly, with a median age at the time of 
presentation in excess of 60 years. However, many clinical trials in AML fail to 
recruit elderly adults due to a combination of strict entry criteria, or physician or 
patient bias. Thus, clinical outcome data from many trials may not be readily 
applicable to older patients with the disease. Furthermore, because the clinical 
outcome for many older patients with AML is frequently poor, elderly patients 
who receive intensive chemotherapy with curative intent are frequently selected 
for treatment on clinical criteria rather than on objective prognostic criteria that 
may define clinical outcome. 
The karyotype at the time of presentation may be considered one of the most 
important prognostic factors in adult AML. Therefore, the aim of this thesis were 
firstly to analyse the clinical outcome data from a cohort of elderly patients 
managed at a single centre in order to document the cytogenetic features of AML 
in an elderly population, to define the prognostic importance of presentation 
karyotype in the elderly, and to identify other prognostic factors. Retrospective 
analysis clearly demonstrated improved clinical outcome for older patients with 
AML over time, primarily as a consequence of improved supportive care and the 
delivery of more intensive chemotherapy. In addition, 'unfavourable' 
presentation karyotype, increasing age and raised serum LDH were found to 
correlate with poor clinical outcome 
Molecular cytogenetic techniques based upon fluorescence in-situ hybridisation 
technology offer the chance to detect and analyse cytogenetic aberrations at a 
higher resolution than can be achieved with conventional techniques. The 
cytogenetic data provided by comparative genomic hybridisation and mulitplex 
fluorescence in-situ hybridisation when used in the analysis of elderly patients 
with AML were found to correlate well with results obtained by conventional 
methods. Importantly, additive cytogenetic data were more likely to be provided 
if multiplex-fluorescence in-situ hybridisation was used in the analysis of cases 
with marker chromosomes or in cases with complex karyotype, although the 
technique was limited by an inability to reliably detect telomeric translocations. 
In addition, although both techniques can be used to complement conventional 
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Cytogenetic symbols and abbreviated terms 
amp Amplified signal 
arrow From - to, in detailed system 
cgh Comparative genomic hybridisation 
colon, single Break, in detailed syste 
comma Separates chromosome numbers, sex chromosomes, and 
chromosome abnormalities 
dim Diminished signal intensity 
del Deletion 
der Derivative chromosome 
dic Dicentric chromosome 
dim diminished signal 
dup Duplication 
enh Enhanced signal intensity 
fish Fluorescence in situ hybridisation 
hsr Homogeneously staining region 
i Isochromosome 
idem Denotes the stemline karyotype in subclones 
idic Isodicentric chromosome 
ins Insertion 
inv Inversion 
mar Marker chromosome 
mfish multiplex in situ hybridisation 
minus sign Loss 
P Short arm chromosome 
parentheses Surround structurally altered chromosomes and breakpoint 
plus sign W Gain 
rev ish Reverse in situ hybridisation including comparative genomic 
hybridisation 
q Long arm of chromosome 
question mark Questionable identification of a chromosome or chromosome structure 
r ring chromosome 
semicolon Q Separates altered chromosomes and breakpoints in structural 
rearrangements involving more than one chromosome 
t Transloation 
tel Telomere 
wcp Whole chromosome paint 
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Chapter One: General Introduction 
Chapter 1 
Historical overview 
Acute myeloid leukaemia (AML) is the name given to a group of neoplastic 
disorders characterised by the uncontrolled rapid proliferation and accumulation of 
malignant myeloid blasts in the bone marrow and other haemopoietic tissues. If the 
patient is untreated and unsupported the disease has a median survival of less than 
three months (Southarn et al., 1951). Death frequently results from infection, 
haemorrhage or both, as a direct consequence of bone marrow failure. 
The first documented cases of leukaemia were described independently in 1845. 
The published reports were of a series of cases in which patients died having 
presented with fever, lethargy, bleeding, abdominal swelling together with changes 
in the colour and consistency of the blood (Bennett, 1845; Craigie, 1845; Virchow, 
1846). Virchow noted at postmortem a reversal in the normal ratio of red to white 
cells in the blood. He subsequently used the term "Weisses Blut"', and later 
introduced the term leukaemia in his description of similar cases. Virchow later 
reported that splenic and lymphatic types of leukaemia existed, and that they could 
be distinguished from each other on the basis of morphological similarities between 
the leukaemic cells and the normal cells of the splenic and lymphatic tissues. Whilst 
Bennett and Craigie assumed that the changes in the blood were as a result of a 
suppurative process, Virchow believed that a disease specific to the splenic and 
lymphatic tissues was responsible for an increase in the number of white cells in the 
blood. Subsequent history has shown that Virchow was fundamentally correct in 
this interpretation. 
Although the first documented case of acute leukaemia was reported in 1857 
(Friedrick, 1857), the term acute leukaemia was introduced in 1889 when it was 
used in the description of a rapidly fatal case of leukaemia (Ebstein, 1889). 
Advances in the histological examination of blood occurred in the late nineteenth 
century with the introduction of polychromatic stains, and an appreciation of the 
common origin of red and white cell precursors following the description of 
myeloblasts and myelocytes. These findings ultimately led to the distinction 
between myeloid and lymphoid leukaemia. 
I 
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Once established as a clinical entity a treatment for leukaemia was soon discovered. 
In the late nineteenth century the arsenicals in the form of Fowler's tonic were 
found to induce transient but unpredictable 'remission" in Patients with chronic 
myeloid leukaemia (CML). By the beginning of the twentieth century radiotherapy 
was shown to be beneficial in the clinical management of chronic leukaemia, with 
only marginal benefit in acute leukaemia. Definitive cures for acute leukaemia 
remained anecdotal. In 1930 a case in which a patient with AML achieved a durable 
remission following therapy with arsenic, mesothorium, and finally two whole 
blood transfusions from a sibling was reported (Gloor, 1930). The leukaemic blasts 
cleared from the blood soon after transfusion and the author attributed part of the 
success to blood transfusion, and although dismissed at the time, it seems likely 
that this was the first documented case of a graft versus leukaemia effect. The 
introduction of blood transfusion for the correction of anaemia in the leukaemic 
patient was noted to induce remission by others (Dreyfus 1948), and led to the 
rationale for exsanguination transfusions in the early 1950"s. Unfortunately the 
response to transfusion were at best temporary and often unpredictable. 
The foundations for the chemotherapeutic treatment of leukaemia were established 
in the 1940s with the discovery and exploitation of the alkylating agents, and the 
introduction of antimetabolite therapy. Post mortem examinations of soldiers who 
died from mustard gas exposure during World War I and II revealed that nitrogen 
mustards produced bone marrow hypoplasia and peripheral cytopenia in those 
exposed (Zubrod, 1979). Therapeutic alkylators were developed as a result, one 
such drug, mechloromethamine was subsequently introduced and used in the 
treatment of lymphoma and leukaemia. Initial studies demonstrated encouraging 
results in patients with chronic leukaernia, with less impressive results in patients 
with acute leukaemia (Goodman et al., 1946). Subsequent development led to the 
introduction of newer agents, namely busulfan, cyclophosphamide and 
chlorambucil, which are used in the treatment of CML and chronic lymphocytic 
leukaemia today. 
In 1940, the utilisation of sulphonamides in the treatment of bacterial infection led 
to the realisation that the mode of action of these agents was a direct result of the 
inhibition of critical biochemical pathways required for bacterial growth. This new 
theory was applied to cancer chemotherapy in the form of folic acid antagonists or 
antimetabolites. In 1948, aminopterin and pteropterin were used in clinical trials, 
and were shown to induce transient remissions in childhood leukaemia (Farber et 
2 
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al., 1948). Antagonists to purine and pyrimidine synthesis were subsequently 
developed and led to the introduction of 6-mercap top urine, 6-thioguanine together 
with allopurinol, and in the 1960s, cytosine arabinoside (ara-C) (Ellison et al., 1968). 
The third major source of chemotherapeutic agents for leukaemia came with 
introduction of steroids, and anthracycline antibiotics. In 1942, adrenocorticoids 
were shown to induce lymphocyte death, and steroids were subsequently 
introduced in the therapy for both acute and chronic leukaemia. In the following 
decades other naturally derived agents were introduced most notably I- 
asparaginase, the vinca alkaloids and the anthracycline antibiotics (Broome, 1961; 
Johnson et al., 1963). 
Although Farber and others documented remission induction in childhood 
leukaemia with antimetabolite therapy (Faber, et al., 1948), treatment of adults with 
AML remained disappointing. However, moderate improvements were noted with 
the introduction of single agent 6-thioguanine and 6-mercaptopurine, for example, 
in 1957 complete remission (CR) was achieved in 6 out of 18 adult patients with 
AML who received single agent 6-mercaptop urine (Bodley Scott, 1957). In the same 
year, the Medical Research Council set up a steering committee for the evaluation 
of cancer therapy. On the recommendation of the committee a working party was 
introduced in order to examine the possibilities of therapeutic trials in leukaemia. 
The first trial conducted by the working party in 1963 involved the comparison of 
steroid therapy in conjunction with 6-mercaptopurine (Medical Research Council, 
1963). 
The treatment of AML with single agent chemotherapy made little impact until the 
introduction of ara-C. Cytosine arabinoside was first used for the treatment of AML 
during the late 1960's (Freireich, 1987). It was recognised that the drug had a short 
half life of 15 minutes when injected intravenously and that optimal responses were 
achieved when ara-C was administered as a continuous infusion over a5 to 10 day 
period. Initial studies in which ara-C was used in AML produced complete 
remissions ranging from 9 to 33% (reviewed in Rohatiner and Lister, 1996). 
However, when administered as a continuous infusion, single agent ara-C resulted 
in CR rates of between 25-55% in AML (Crowther et al., 1973). Further improvement 
in remission CR rates was not achieved until the introduction of combination 
chemotherapy in the early 1970's. A regimen consisting of the anthracycline 
antibiotic daunorubicin (45-60mg /M2 intravenously) on days 1-3 and ara-C 
(1OOMg/M2 intravenously by continuous infusion) on days 1-7 known as '3+7' 
3 
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became established as standard remission induction therapy for AML (Rai et al., 
1981; Preisler et al., 1987). In comparison to single agent ara-C, the '3+7' regimens 
typically produce remission rates ranging from 50-75% depending on patient age 
(Appelbaum et al., 1998). In attempt to improve remission rates further still, various 
permutations of the basic '3+7' regimen have been investigated. These have 
included modification of the dose and duration of the drugs, choice of 
anthracycline, and the addition of additional drugs like etoposide, and 6- 
thioguanine. Thus in 1986 the 8 th MRC AML reported CR rates of 67% and median 
duration of first remission of 15 months with 'DAT" a combination of daunorubicin, 
ara-C and 6-thioguanine (Rees et al., 1986). With current chemotherapy, an overall 
survival of between 10-30%, at 5 years, can be achieved in young adult patients, 
whilst overall survival falls to less than 10% at 5 years in patients aged 60 years or 
more, treated similarly (Bennett et al., 1997). 
In the early 1950's, laboratory experiments demonstrated that it was possible to 
'frescuet animals that had received a lethal dose of radiation by the intravenous 
administration of bone marrow cells. Subsequently, patients with end stage 
haematological malignancies were treated with chemo /radiotherapy followed by 
bone marrow infusion. Although generally unsuccessful, it was possible to 
demonstrate transient engraftment in some patients. The discovery of the human 
leucocyte antigen system (HLA) and the development of HLA typing 
methodologies led to the modern era in bone marrow transplantation. In the early 
1970's a number of centres used allogeneic bone marrow transplantation in patients 
with acute leukaemia in whom conventional chemotherapy had failed, and were 
able to document long term disease free survival in a significant number of patients 
(Thomas et al., 1975). The use of autologous bone marrow 'transplants" in the 
management of haematological malignancy became commonplace in the 1980's. 
Currently, allogeneic, autologous, matched unrelated and non-myeloablative 
transplants are used as valid treatment modalities in the management of AML. 
However, the morbidity and mortality associated with these procedures coupled 
with the limited availability of suitable donors restricts the practical use of these 
techniques to patients less than 50 years of age. 
The profound pancytopenia that accompanies the use of cytoreductive 
chemotherapy in AML treatment is responsible for the significant morbidity and 
mortality associated with remission induction and consolidation chemotherapy. 
Indeed treatment-related death due to infection is a major determinant of treatment 
4 
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failure in AML remission induction, accounting for up to 70% of (Bodey et al., 1982). 
In the elderly, the incidence of severe infection during induction therapy has been 
estimated at 20% (Stone et al., 1995). Although patients with AML are at risk of 
bacterial, viral and fungal infection, in practice whilst neutropenic, bacterial 
infections are the most frequent and often the most serious cause of infection. The 
risk of bacterial infection increases significantly when the neutrophil count falls 
below 0.5xlO'/l and is especially pronounced when below O. IxIO'/I. The duration 
of neutropenia also determines risk, and is particularly important in the elderly 
who often have prolonged periods of neutropenia following remission induction 
therapy due to poor bone marrow reserve, or pre-existing myelodysplasia. Thus the 
empiric use of broad spectrum antibiotics, which cover both gram-negative as well 
as gram-positive organisms is an established part of supportive care for patients 
with AML, and has led to a reduction in patient mortality (Hughes et al., 1990). 
Likewise, since they became routinely available in the mid 1970's, the prophylactic 
use of platelet concentrates, together with antibacterial and antifungal mouth-care 
and indwelling venous catheter usage has significantly reduced the morbidity and 
mortality of AML patients receiving intensive chemotherapy. 
5 
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Epidemiology and Aetiology of Acute Myeloid Leukaemia 
The annual incidence of AML in the United Kingdom is 3/100,000 person years 
(Cartwright et al., 1997). The incidence rises with increasing age, peaking at 
10.5/100,000 person years for patients over the age of 75 years. Similar rates of 
incidence have been reported in other countries in Northern Europe and North 
America. 
With improvements in the standard of living as well as better health care provision, 
it has been estimated that there will be a 38% increase in the number of individuals 
aged over 60 years by 2031. If the incidence of AML remains static during this 
period, then a 35-40% increase in cases of AML in patients aged over 60 years may 
occur (Johnson & Liu Yin, 1993). Clearly if these figures are correct, they signal a 
significant change in the in-patient practice for those involved in the management 
of AML. 
Although the aetiology of AML remains unknown in the vast majority of cases, a 
number of diseases are known to predispose to the condition including the 
myeloproliferative disorders (Table 1-1). Specific genetic abnormalities have also 
been implicated in the pathogenesis of leukaemia. For example, leukaemia is 20 
times commoner amongst individuals with Downs syndrome. Furthermore, 
congenital disorders that result in chromosomal fragility or impaired DNA repair 
are also associated with an increase risk of AML. These disorders include Fanconi 
anaemia, Blooms syndrome, and Ataxia telangiectasia. 
Epidemiological studies of disease permit the identification of disease related risk 
factors. In AML three causal environmental factors have been identified, namely: i. 
lonising radiation, ii. Chemotherapy, iii. Benzene exposure. 
Compelling evidence linking radiation exposure to the development of leukaemia 
came from the long term follow-up of survivors of the atomic bomb explosions in 
Hiroshima and Nagasaki. Following the nuclear bombing of these cities the Atomic 
Bomb Casualty Commission was established by the United States in order to study 
the health trends of individuals exposed to 
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Table 1-1 








Clonal haemopoietic diseases 
Chronic myeloid leukaemia 
Primary myelofibrosis 
Polycythaen-da 






Identical sibling with AML 
Non-identical sibling with AML 
Wiskott-Aldrich syndrome 
Combined immunodeficiency/ Congenital agrantflocytosis 
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radiation. Studies carried out by the agency, and others, demonstrated a higher 
incidence of AML and CML in individuals exposed to radiation (Doll, 1995). 
Furthermore the development of leukaernia following exposure to radiation was 
found to be dose related, with the highest incidence in individuals less than 10 
years, or older than 50 years of age at the time of exposure. Similar observations 
have been found in armed forces personnel who were exposed to nuclear fallout 
(Caldwell et al., 1983). In the civilian setting landmark studies in the 1960"s 
illustrated an increased incidence of AML amongst patients who received low dose 
radiation for ankylosing spondylitis and in women who received radiotherapy for 
cervical cancer (Moloney, 1987). 
The incidence of myelodysplasia (MDS) and AML in individuals who have 
received chemotherapy for malignant and non-malignant disorders has been found 
to be higher than in the general population (Devereux, 1991; Hoyle et al., 1989). 
Commonly used alkylating agents, which include cyclophosphamide, chlorambucil 
and busulphan, have been associated with an increased risk of AML. In Hodgkin's 
disease, the cumulative risk of AML in patients who received alkylating agents is 
13% at 7 years, in contrast to less than 1% in patients who receive non-alkylating 
agents. Therapy-related AML (t-AML) induced by this group of drugs typically 
occurs some 2 to 8 years after exposure, and is often associated with karyotypic 
abnormalities such as complete or partial loss of chromosome 5 or 7, and or 
complex karyotype. The second group of chemotherapeutic agents commonly 
associated with t-AML are the topoisomerase II inhibitors. Acute myeloid 
leukaemia arising as a direct result of exposure to these agents is characterised by a 
short latency period of between 2 to 3 years, (typically without preceding MDS), 
and with characteristic cytogenetic aberrations involving chromosome sub-region 
11 q23. In both instances the risk of t-AML increases with the cumulative dose of the 
chemotherapeutic agent received, and with the combination of chemotherapy and 
radiotherapy. 
Chronic exposure to benzene is associated with an increased incidence of AML 
(Infante et al., 1977; Rinsky et al., 1987). Other environmental agents, including 
electromagnetic fields, metal fumes, polychlorinated biphenyls, and cigarette 
smoking have been linked with leukaemogenesis. However the link between AML 
and these leukaemogens is less pronounced. 
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Classification of Acute Myeloid Leukaemia 
Classification systems for AML rely upon the morphological, cytogenetic and 
immunophenotypic features of the leukaemic blast cells. In practice all three 
modalities are used in conjunction with each other, but historically the classification 
of AML has been based upon the morphology of leukaemic blast cells. 
French American British (FAB) Classification 
In 1976 the French American British (FAB) working party proposed a classification 
system for acute leukaemia based upon the morphological appearance of 
Romanosky stained blood and bone marrow smears (Bennett et al., 1976). In order 
to establish the diagnosis of AML, the FAB classification requires that at least 30% 
of nucleated cells in the bone marrow must be leukaen-dc blasts. Since its inception 
a number of modifications to the FAB classification have been made incorporating 
additional histochernical stains as well as immunophenoyping, in an attempt to 
recognise all existing AML variants (Bennett et al., 1985a; Bennett et al., 1985b; 
Bennett et al., 1991). Currently eight subtypes of AML are recognised by the FAB 
system (Table 1-2). The diagnostic recommendations proposed by the FAB group 
have been widely accepted and are now used by most groups involved in clinical 
trials and studies of AML, allowing direct comparison between groups in terms of 
disease. 
World Health Organization (WHO) Classification 
The World Health Organization (WHO) classification of haematological 
malignancy was introduced in 1999 with aim of producing a more clinically 
relevant classification system for leukaemia by utilising morphological, cytogenetic, 
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Chapter Two : AML in the elderly, St Bartholomew's Hospital (1969-1999) 
Table 1-3 
WHO classification of acute myeloid leukaemia 
AML with recurrent cytogenetic translocations 
AML with t(8; 21)(q22; q22), AMLI(CBF-alpha)/ETO 
Acute promyelocytic leukaemia (AML with t(15; 17)(q22; qll-12) and 
variants, PML/RAR alpha 
AML with abnormal bone marrow eosinophils 
inv(16)(pl3q22) or t(16; 16)(p13; q11), CBFP/MYH11X) 
AML with 11q23 (MLL) abnormalities 
AML with multilineage dysplasia 
With prior myelodysplastic syndrome 
Without prior myelodysplastic syndrome 
AML and myelodysplastic syndromes, therapy-related 
Alkylating agent-related 
Epipodophyflotoxin-related (some may be lymphoid) 
Other types 
AML not otherwise categorised 
AML minimally differentiated 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monocytic leukaemia 
Acute erythroid leukaen-da 
Acute megakaryocytic leukaemia 
Acute basophilic leukaen-da 
Acute panmyelosis with fibrosis 
Acute biphenotypic leukaemias 
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Unlike the FAB system, the percentage of bone marrow blast infiltration required 
for the diagnosis of AML was reduced to 20% in order to reflect the similarity in 
clinical outcome between patients with refractory anaemia with excess blasts in 
transformation, and patients with AML and more than 30% blast cell infiltration. 
The classification system also makes the distinction between subtypes of AML 
based upon distinct non-random primary cytogenetic aberrations which 
influence leukaemia biology, including translocations which involve core binding 
factors and retinoic acid receptors. Furthermore, therapy related AML and 
myelodysplastic syndromes are classified according to the chemotherapeutic 
agents that have been identified as aetiological factors. 
Prognostic Factors in Acute Myeloid Leukaemia 
A number of clinical and biological parameters have been identified as reliable 
predictors of patient response to curative therapy as well as relapse risk. These 
factors include patient performance status, and tumour burden, manifest by high 
white count or hepatosplenomegaly. Other more reliable co-variates are currently 
used to guide appropriate therapy in a 'risk adapted" approach, and include 
patient age, karyotype and morphological response to therapy. 
Patientage 
The chronological and biological age of an adult patient may differ considerably, 
particularly in the elderly. However, despite an association with other prognostic 
factors whose incidence increase with age, chronological age has been shown to 
be a major determinant of clinical response, and relapse risk (Sorensen et al., 1993; 
Walters et al., 1987). The highest CR rates and longest disease free survival are 
seen in children and adolescents between the ages of I and 15 years. By 
comparison, patients over the age of 60 years have poor CR rates and overall 
survival (Copplestone & Prentice, 1988; Hiddemann et al., 1999). 
Presentation karyotype 
Cytogenetic aberrations can be documented in the majority of AML patients at 
the time of diagnosis, and have been shown to be independently predictive of 
treatment response and relapse risk (Bloomfield et al., 1984; Grimwade et al., 
1998; Mrozek et al., 1997). The cytogenetic aberrations associated with high CR 
rates and favourable outcome occur more frequently in younger patients and 
include t(15; 17), inv(16), and t(8; 21). Conversely, monosomy 5, and 7 as well as 
12 
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complex karyotype (characterised by three or more distinct chromosomal 
abnormalities) are associated with reduced CR rates and are more frequent in the 
elderly at the time of presentation. 
Initial morphological response to therapy 
Failure to clear blast cells from the marrow after the first course of chemotherapy, 
particularly if blast cells number more than 20%, is associated with drug 
resistance and a diminished response to subsequent courses of chemotherapy 
(Estey, 2000a). Indeed, such failure to respond to standard chemotherapy can 
considered an indication to try investigational therapies (O'Donnell et al., 1996). 
Drug resistance has been shown to correlate with the expression of a 170 KD 
membrane glycoprotein coded by the MDR-1 gene. The immunological and 
functional expression of this protein, and other functionally related proteins such 
as lung resistance protein, occur more frequently in elderly patients with AML, 
and correlate with disease resistance and reduced CR rate (Leith et al., 1997; 
Lowenberg & Sonneveld, 1998). Modulators of drug resistance such as PSC833 
are currently under evaluation, as a means of overcoming drug resistance and 
improving clinical outcome. 
Acute Myeloid Leukaemia in the Elderly 
Although AML is generally perceived to be a disease of the young, it is in reality 
a disease that predominantly occurs in the elderly, with a median age at 
presentation of 64 years (Brinker, 1982). Frequently the clinical trials 
investigating curative therapy in AML have low rates of recruitment for patients 
over the age of 60 years often as a result of misconceptions about the benefits of 
such trials for older patients on the part of physicians, patients and their families 
(Hutchins et al., 1999; UKCCCR, 2000). In addition the stringent eligibility criteria 
imposed by many trials, coupled with logistic barriers, also contribute to the 
reduced recruitment of older patients. For these reasons the results from clinical 
trials may not always be strictly applicable to the elderly. Clearly, with an ageing 
population the number of elderly patients referred to tertiary centres for 
management of AML is set to rise as mentioned above. Therefore it is important 
not only to understand the nature of the disease in the older patient, but to also 
develop improved management strategies for these patients. 
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Characteristics of AML in the elderly 
It is important to realise that although the definition of "elderly' by an arbitrary 
defined age cut-off point (usually an age of 60 years or more at the time of 
diagnosis) is common practice particularly for the purposes of clinical trials, it is 
not always ideal. Variation in cardiovascular, renal and respiratory baseline 
function, and reserve capacity occur with increasing age, and are often most 
marked in the elderly, particularly between the ages of 70-80 years (Cohen, 1999). 
Consequently, biological age may not strictly reflect chronological age. 
If the arbitrary definition of elderly is applied then the overall outcome of elderly 
patients with AML is much worse than similarly treated younger patients with 
de-novo AML. Conventional remission induction regimens produce CR in 
approximately 70-80% of young adults (Rees et al., 1986). With consolidation 
chemotherapy and or bone marrow transplantation between 30-45% of those 
who achieve remission will be cured (Buchner, 1993). Thus, approximately 20% 
of young adults achieve long term disease-free survival with current AML 
therapy (Bishop, 1999). By comparison, CR rates of 40-55% in the elderly are 
commonplace with similar induction chemotherapy regimens, whilst only 5-10% 
achieve durable disease free remissions (Hiddemann et al., 1999). Furthermore, 
the incidence of treatment-related deaths, as a result of induction chemotherapy, 
increases with age. For example, in reported series treatment-related deaths 
range from 12-44% in elderly patients (Lowenberg, 1996), compared to 10-15% in 
younger patients (Bishop, 1999). The relatively poor outcome of elderly AML 
patients may be explained by a combination of intrinsic disease resistance, as a 
consequence of distinct biological factors, and patient related factors that result in 
reduced tolerance to myelosuppressive chemotherapy. 
Pathophysiology of AML in the elderly 
A number of biological characteristics that are associated with poor response to 
therapy are found with increased frequency in the elderly and suggest that AML 
biology in this group of patients may be distinct from the disease biology in de 
novo AML associated with younger patients. 
Patient karyotype at the time of presentation has been shown to be an important 
prognostic factor in AML (Bloomfield et al., 1984; Mrozek et al., 1997), predicting 
CR rate and overall survival. Compared to younger patients the elderly have a 
higher frequency of 'unfavourable' cytogenetic aberrations at the time of 
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diagnosis. These include complex karyotype, monosomy 5 and monosomy 7 
(Leith et al., 1997). 
A significant number of elderly patients with AML have a history of an 
antecedent haematological disorder (AHD), defined as an abnormal blood count 
present for at least one month without requirement of a bone marrow biopsy. 
Furthermore the incidence of MDS is thought to increase with age, and may be as 
high as 20 to 30% in elderly AML patients compared to 15% in younger AML 
patients (Johnson & Liu Yin, 1993; Oscier, 1987). Both preleukaemic MDS and 
AHD have been found to correlate with reduced CR rates, disease-free survival 
and overall survival, particularly if present for at least 2 months prior to 
presentation with AML (Gajewski et al., 1989). 
Resistance to chemotherapy is associated with the expression of a number of 
membrane transporter proteins, which produce a multi-drug resistance 
phenotype. These proteins include P-glycoprotein encoded by the multi-drug 
resistance gene (MDR-1), multi-drug associated protein (MRP) and lung 
resistance protein (LRP). At the time of diagnosis, antigenic and functional P-gp 
expression can be demonstrated in 71% and 58% of leukaemic blast cells from 
elderly patients respectively. In contrast, younger patients have antigenic and 
functional P-gp expression of 35% and 41%, respectively (Leith et al., 1999). The 
intrinsic drug-resistance associated with elderly AML results in a reduced CR 
rate (Leith et al., 1997), and may result in an increased treatment-related death 
rate as a result of delayed normal haemopoiesis following induction 
chemotherapy. 
The leukaemic blasts in elderly AML are thought to arise from a pluripotent 
CD34+ stem cell, more frequently than in younger patients. Thus as a result, 
'clonal remissions, resulting in the persistence of the leukaemic cells, may occur 
more frequently in the elderly than in younger adults (Fialkow et al., 1987). 
Many of the biological characteristics of elderly AML are shared with t-AML, 
including the high incidence of poor outcome cytogenetics and the association 
with preleukaernic MDS/AHD and multi-drug resistant phenotype. Both types 
of AML are characterised by a poor response to conventional induction 
chemotherapy. For this reason AML in the elderly and t-AML should be 
considered as being biologically distinct from de-novo AML in younger patients. 
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Management of AML in the elderly (curative treatment strategies) 
Early clinical studies of chemotherapy in elderly AML patients demonstrated 
that CR could be achieved using a combination of an anthracycline and 
cytarabine (Peterson & Bloomfield, 1977). Furthermore, a comparison between 
standard induction therapy and a 'watch and wait' approach where mild 
myelosuppressive chemotherapy is given only to control the symptoms of AML, 
demonstrated a significant advantage in terms of CR (58% v 0) and overall 
survival (21 weeks v 11 weeks) for patients who received intensive 
chemotherapy, whilst the number of days spent in hospital by patients in the two 
groups was identical (Lowenberg et al., 1989). Thus it can be argued that elderly 
patients with AML should receive aggressive curative therapy if at all possible. 
Presently, typical CR rates using "3+7' anthracycline/cytarabine regimens range 
from 40-55% in patients 60 years or older (Dombret et al., 1995; Liu Yin et al., 1991; 
Lowenberg et al., 1998; Lowenberg et al., 1997), compared to 70% or more in 
younger adults. In an attempt to improve efficacy and reduce treatment-related 
toxicity, daunorubicin has been substituted with other anthracyclines, or 
anthracendiones namely idarubicin or mitoxantrone. Higher CR rates with 
mitoxantrone in combination with cytarabine have been reported in single centre 
studies (Liu Yin et al., 1991; MacCallum et al., 1995). However, when the Eastern 
Cooperative Oncology Group (ECOG) prospectively compared three induction 
regimens in the elderly: daunorubicin 45mg/m' v mitoxantrone 12mg /M2 V 
idarubicin 12mg /M2 - all given intravenously for 3 days with identical doses of 
cytarabine 100Mg/M2 for 7 days, as well as identical consolidation 
chemotherapy. The three regimens were of identical efficacy, with a median CR 
rate of 42% and disease free survival of 14 months, furthermore treatment related 
mortality was lowest in patients who received mitoxantrone at (16%), although it 
was not statistically significant (Rowe et al., 1998). Thus in older patients with 
AML, the optimal anthracycline and dose has yet to be determined. 
Low dose curative chemotherapy has been investigated in the elderly. Although 
some authors have reported impressive results, in terms of CR rate with 
low dose 
cytarabine regimens (Manoharan, 1998), a large retrospective analysis of 
751 
patients revealed that CR rates using low dose cytarabine regimens were at 
best 
32%, and that the use of such regimens was associated with prolonged 
myelosuppression (Cheson et al., 1986). Therefore, current evidence would 
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suggest that although CR can be achieved with low dose cytarabine, standard 
dose curative therapy is more efficacious, and should be used in preference. 
The precise benefit of post-remission therapy in the elderly has not been 
documented extensively. In younger patients with AML it is widely accepted 
that post-remission chemotherapy is required in order to produce durable 
remissions. Current consolidation therapies entail the administration of 
chemotherapy at similar doses to those used at induction. In recent years, dose 
escalation of cytarabine has been investigated. In a trial conducted by the Cancer 
and Leukaemia Group Ba dose-response effect in terms of disease-free and 
overall survival was observed in patients less than 60 years, with cytarabine at 
3g/m' being superior to 400mg/m' and 100mg/m'(Mayer et al., 1994). 
Unfortunately, in older patients (32% of the cohort) treatment was poorly 
tolerated, with significant neurotoxicity in those patients receiving 3g/ M2 
cytrabine. Importantly, no discernible difference between the treatment dose of 
cytarabine was seen in the elderly group studied. Despite the findings some 
authors suggest that post-remission therapy using lower doses of cytarabine 
(1.5g/M2) are better tolerated in older patients, with overall survival at 2 years of 
30% (Rowe, 2000). 
Consolidation chemotherapy in elderly AML patients may seem logical based 
upon results in younger adults. However, the optimal therapy and number of 
courses remain unknown. Furthermore, the morbidity and mortality associated 
with curative therapy frequently preclude the routine use of post-remission 
therapy in many older patients, particularly those over the age of 70 years. Thus, 
until extensive randomised studies of consolidation therapy in the elderly are 
conducted, it would seem sensible to plan consolidation therapy on a case by 
case basis for older patients. 
Complications during remission induction therapy: Patient related factors 
With current curative therapy, approximately 30% of elderly patients develop 
complications associated with induction chemotherapy resulting in treatment- 
related death (Lowenberg, 1996). The most frequent cause of death in these cases 
can be attributed infection, often during the period of bone marrow aplasia 
(Kimmick et al., 1997). The risk of infection is a direct result of quantitative and 
qualitative neutropenia due to bone marrow infiltration, and bone marrow 
hypoplasia resulting from chemotherapy. 
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The normal physiological changes that occur with increasing age, result in 
reduced cardiac function and vessel wall compliance, as well as a decline in 
pulmonary function. Furthermore, the presence of co-morbid disease such 
ischaemic heart disease and hypertension, result in the significant reduction of 
cardiac physiological reserve (Cohen, 1999). Consequently, the elderly are less 
able to tolerate the haemodynamic consequences of severe infection. Thus 
treatment-related deaths as a direct result of infection occur more frequently in 
elderly patients than in younger adults. In addition to co-morbid disease, 
physiological age related changes affecting renal and hepatic function result in 
pharmacokinetic and pharmacodynamic changes that increase the systemic 
bioavailability and plasma concentrations of antineoplastic agents. When 
coupled with the reduced haernopoietic reserve of elderly patients, the systemic 
and haernatological toxicity associated with chemotherapy may often be 
profound (Balducci et al., 1988; Kimmick et al., 1997; Rubin et al., 1992). 
Supportive care 
The empiric use of broad-spectrum antibiotics is central to the supportive care of 
the neutropenic patient and thus all patients with acute leukaemia (Hughes et al., 
1990). The provision of red cell concentrates to febrile neutropenic patients, 
particularly during severe infection, augments tissue oxygenation and is 
therefore also an essential part of patient management. Additional supportive 
care measures aimed at reducing the incidence of infection include systemic 
antifungal therapy, antiseptic and antifungal mouthwash, nursing patients in 
rooms fitted with high efficiency particulate air filter (HEPA) to reduce air borne 
pathogens, and the use of colony stimulating factors during the period of 
neutropenia. It is important to emphasise that the majority of nosocomial 
infections require a human vector for transmission. Thus general hygiene 
procedures for health care workers in contact with patients, including hand 
washing before and after patient contact, should be considered an integral part of 
supportive care aimed at reducing infection (Handwashing liason group, 2000). 
Haemostatic support for patients receiving curative therapy is also a vital part of 
supportive care. Until platelet concentrates became routinely available in the mid 
1970's, haemorrhagic complications attributable to the use of myelosuppressive 
therapy was a major cause of patient morbidity and mortality (Lister et al., 1981). 
Furthermore, although not strictly thought of as supportive care, the inclusion of 
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all-trans retinoic acid in curative regimens for patients with AML M3 has led to a 
significant reduction in early deaths due to haemorrhage in patients with this 
sub-type of AML (Barbui et al., 1998). 
Growth factor therapy 
The therapeutic rationale for the use of haemopoietic growth factors in AML 
therapy is two fold. Firstly, the use of colony-stimulating factors (CSF) may 
shorten the duration of neutropenia following chemotherapy with a concomitant 
reduction in morbidity and mortality from infection. Secondly in vitro studies 
have shown that certain CSF may sensitise AML blasts to chemotherapy and thus 
co- administration of growth factors with chemotherapy may enhance CR. 
Commercially available recombinant human haemopoietic CSF have been 
available for over a decade. Two CSF, namely granulocyte colony stimulating 
factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) 
have been extensively evaluated in the treatment of AML. Although both GM- 
CSF and G-CSF have been shown to induce AML blast proliferation in-vitro, 
their use in AML therapy appears to be safe. Several trials in which both growth 
factors have been used as supportive agents in AML therapy have now been 
reported. The use of G-CSF and GM-CSF is associated with a reduction in the 
number of days of neutropenia during induction therapy (Dombret et al., 1995; 
Lowenberg et al., 1997; Rowe et al., 1995), although only one trial has reported a 
significant reduction in treatment-related deaths (Rowe et al., 1995), and in one 
other a significantly higher CR rate was reported in patients who received G-CSF 
(Dombret et al., 1995). Thus the results of these studies do not present a 
convincing argument for the routine prophylactic use of G-CSF or GM-CSF in 
elderly patients receiving intensive chemotherapy. 
Attenuated dose chemotherapy 
Attempts to reduce treatment-related deaths in patients receiving intensive 
chemotherapy has led to the investigation of attenuated dose remission induction 
chemotherapy. In trials in which standard and attenuated regimens 
have been 
compared, results have shown that attenuated regimens result 
in fewer 
treatment-related deaths, usually at the expense of reduced CR rates. For 
example the MRC AML 9 study which included elderly patients, 
demonstrated 
reduced CR, and survival, despite less induction 
deaths for patients receiving 
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DAT (1+5) compared to DAT (3+10) (Rees et al., 1996). Similarly CALGB trials 
have shown higher CR rates with intensification of induction (Preisler et al., 
1987). 
Individualised drug dosing has been shown to improve outcome and reduce 
treatment-related toxicity in children with acute lymphoblastic leukaemia (Evans 
et al., 1998; Wall et al., 2000). By applying a similar rationale to older patients with 
AML it may be possible to compensate for the age-related change in hepatic and 
renal function, and so reduce treatment related toxicity and also improve CR rate 
(Desoize & Robert, 1994). 
Immunotherapy 
The morbidity and mortality associated with myeloablative chemotherapy may 
be reduced or avoided with the introduction of monoclonal antibody therapy. 
The CD33 cell membrane antigen, which is highly expressed on leukaemic 
myeloid blasts cells, has been used as the primary target for monoclonal antibody 
therapy in AML. Initial studies using unmodified murine antiCD33 
demonstrated a transient reduction in the number of circulating blasts in patients 
with AML (Caron et al., 1998). Humanised antiCD33 conjugated with 
calicheamicin, a cytotoxic antibiotic, has been evaluated in phase I and 11 studies 
(Sievers et al., 1997; Sievers et al., 1998). It has been shown to induce CR, with an 
overall response rate of 43% and is associated with less toxicity than standard 
chemotherapy. Common adverse reactions include fever, chills, asymptomatic 
hypotension and elevation of liver enzymes. Clearly targeted immunotherapy 
using monoclonal antibody may offer a new modality of treatment that is both 
effective and less toxic than conventional chemotherapy. However, the optimum 
role of such agents in AML, particularly in the elderly, will only determined by 
the results of phase 11 and III studies. 
Cytogenetics of Acute Myeloid Leukaemia 
Over the last forty years cytogenetic analysis has led to improvements in the 
diagnosis of AML, and to a greater understanding of leukaemogenesis. 
Furthermore, current treatment protocols used in AML now utilise cytogenetic 
data in order to stratify patients in terms of prognosis, and treatment. 
20 
Chapter Two: AML in the elderly, St Bartholomew's Hospital (1969-1999) 
Background 
The first consistent chromosomal abnormality in human cancer was documented 
in 1960 when a shortened G group chromosome, now called the Philadelphia 
chromosome (Ph), was documented in patients with CML (Nowell & 
Hungerford, 1960). The true nature of this chromosomal aberration was clarified 
in 1973 when it was demonstrated that the Ph chromosome arose as a direct 
result of a translocation between the long arm of chromosome 9 and 22 
[t(9; 22)(q34; q11.2)] (Rowley, 1973). This work led to a search for cytogenetic 
aberrations in other haematological malignancies, including AML. The results 
were initially disappointing; however, with the introduction of chromosome 
banding techniques in the early 1970's (Caspersson et al., 1970), specific 
chromosomal aberrations were detectable in up to 50% of patients with AML. 
Improvements in cell culture techniques and the introduction of high resolution 
banding protocols led to an improvement in the rate of detection of chromosomal 
aberrations and the belief that the majority of patients with AML had an 
abnormal karyotype (Yunis et al., 1981). 
In adult patients with AML, clonal chromosomal aberrations can be detected in 
approximately 60-80% of cases (Heim & Mitelman, 1995). Thus, a significant 
percentage of patients with AML still present with a normal karyotype. This may 
be attributable to the existence of non-neoplastic cells dividing preferentially in 
vitro in a number of cases. However, many patients with normal karyotype at 
presentation maintain a normal karyotype throughout, including at the time of 
relapse. This strongly suggests that AML can occur in the absence of recognised 
microscopic cytogenetic aberrations. Nevertheless with the introduction of 
molecular cytogenetic techniques sub-microscopic chromosomal aberrations can 
now be detected in patients with either normal and abnormal karyotype 
(Caligiuri et al., 1994; Shurtleff et al., 1995; Tosi et al., 1999). 
Cytogenetic analysis 
Conventional karyotype analysis depends upon the ability to arrest dividing 
neoplastic cells in metaphase or prophase, and to achieve suitable spreading, 
fixation and staining of chromosomes prior to microscopic examination. Early 
cytogenetic studies in leukaemia were performed using bone marrow cells that 
had been subjected to short-term culture. This was followed by the introduction 
of more 'direct' methods in which freshly aspirated bone marrow cells were 
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cultured for up to two hours in the presence of colchicine. The direct method was 
considered to be the most appropriate technique for the cytogenetic analysis of 
leukaemic cells, as the distortion of the in vivo population, was kept to a 
minimum by the very short in vitro culture time. However, it was frequently 
recognised that the quality of metaphase chromosomes produced by direct 
methods was often poor, and commonly associated with a low mitotic index, 
particularly in cases of ALL. In order to overcome these problems a variety of 
culture techniques was introduced, with and without cell synchronisation. 
The identification of individual chromosomes in cytogenetic analysis is essential 
and relies upon the use of specific dyes in order to produce transverse bands 
along the entire length of the chromosome. The first banding methods used 
quinacrine mustard in order to create fluorescent transverse bands of variable 
brightness (Q-banding) (Caspersson et al., 1970). Currently the most widely used 
banding methods use Giemsa dye preceded by denaturing techniques in order to 
produce chromosome bands (G-banded). Conventional banding techniques 
provide the most comprehensive assessment of karyotype as both numerical and 
structural abnormalities, including translocations and inversions can be detected 
simultaneously. However, these techniques can only be applied to dividing cells. 
Furthermore, certain chromosomal aberrations may be missed by these 
techniques as a consequence of limited resolution or reduced contrast between 
adjacent bands at chromosomal breakpoint regions. 
In the 1980's, molecular cytogenetic techniques were developed and addressed a 
number of the technical limitations of banding methods. Fluorescence in situ 
hybridisation (FISH) techniques employ fluorescently labelled nucleic acid 
sequences as probes for cellular DNA targets. The most frequently used FISH 
probes in cytogenetic analysis include (i) repetitive sequence probes (ii) whole 
chromosome paints and (iii) locus specific probes. Consequently, it is now 
possible to identify numerical aberrations, components of chromosomal 
rearrangements, and specific DNA sequences by FISH (Kearney, 1999). Unlike 
conventional banding analysis FISH can be applied to non-dividing (interphase) 
cells. Therefore, it is now possible to screen a large number of cells and obtain 
cytogenetic data from a wide variety of source material, including paraffin- 
embedded archival sections, blood and bone marrow smears, by utilising 
interphase FISH. 
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The in situ hybridisation reactions, that form the basis of FISH, are highly specific 
as a direct consequence of the complementarity of base pairing between 
homologous DNA sequences. Thus, FISH affords an inherently objective 
assessment of a cytogenetic aberration, at much higher detection sensitivity (ý! 
Ikb) than can be achieved with banding analysis, which is inherently subjective. 
However, unlike banding analysis, it is only possible to obtain cytogenetic 
information from chromosomes or specific genes that have been probed by FISH. 
Two new FISH-based molecular cytogenetic techniques, comparative genomic 
hybridisation and multiplex-FISH have expanded the limitations of conventional 
FISH methods and allow the screening of the entire genome in one hybridisation 
experiment. 
Comparative genomic hybridisation (CGH) is a molecular cytogenetic technique 
which provides a global view of chromosomal gains or loses (DNA copy number 
change) in genomic DNA derived from a tumour sample. It requires no prior 
knowledge of the karyotype associated with the tumour specimen, and it is not 
dependent upon the presence of dividing cells. The methodology is based on the 
simultaneous in situ hybridisation of differentially labelled total tumour DNA 
and normal DNA, in fixed proportion, to normal human metaphase chromosome 
preparations, under conditions of repeat sequence suppression (Kallioniemi et al., 
1992). The technique has mainly been applied to the study of solid tumour 
cytogenetics, as these tumour types are frequently characterised by a low mitotic 
index and have poor chromosome morphology. Balanced chromosomal 
rearrangements do not alter DNA copy number, and therefore can not be 
detected by CGH. 
Multiplex-FISH (M-FISH) allows the identification of individual chromosomes by 
representing each of the 22 autosomes and the 2 sex chromosomes in a distinct 
colour (Speicher et al., 1996). The technique, which relies upon specific whole 
chromosome paint mixture can be used to identify rearrangements such as 
cryptic translocations, small insertions and marker chromosomes, and can be 
considered complementary to CGH and conventional cytogenetic analysis. 
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Primary chromosomal aberrations 
It has been estimated that up to 55% of patients with AML present with one 
specific chromosomal aberration (Heim & Mitelman, 1995). The cytogenetic 
changes that have been documented include both numerical and structural 
chromosomal aberrations. However, the majority of these aberrations are non- 
random translocations that are leukaemia-specific (Table 1-4). 
Chromosomal translocations are a consistent cytogenetic feature of many types 
of haematological malignancy and are thought to play an important role in the 
initiation of leukaemogenesis (Rabbitts, 1994). The rearrangements that occur as a 
consequence of chromosomal translocation may either disrupt the transcriptional 
regulatory elements of genes, or result in the formation of novel chimeric gene(s) 
as a result of an in-frame fusion of two or more exons either side of the 
breakpoint junction. Chromosomal translocations that 
disrupt the regulatory elements of a gene frequently involve T-cell receptor or 
immunoglobulin heavy chain genes and therefore are associated with lymphoid 
malignancy, whilst gene rearrangements resulting in the formation of chimeric 
genes frequently occur in AML. 
The loss of a tumour suppressor gene through the direct loss of chromosomal 
material or inactivation as a result of mutation has been implicated in the 
pathogenesis of solid tumours such as Retinoblastoma, Wilms tumour, and 
colonic cancer. However, role of tumour suppressor genes in leukaemogenesis is 
less clear. Cytogenetic deletion maps demonstrate that elderly patients with 
AML, and patients with t-AML or MDS frequently lose genetic material from 
chromosome 5 and 7 (johansson et al., 1991; johansson et al., 1993; Mauritzson et 
al., 1998), suggesting that the loss of tumour suppressor gene activity may be 
important in leukaemogenesis. However, putative tumour suppressor gene(s) 
associated with these chromosomal aberrations have yet to be detected. §§ 
The molecular mechanisms through which trisomies in AML exert their 
leukaemogenic potential remains unclear. The ALLI gene is partially duplicated 
in trisomy 11 and has been implicated in leukaemogenesis. However, other genes 
duplicated in trisomy 11 may also be involved (Schichman et al., 1995). 
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Table 1-4 




t(8; 21)(q22; q22) 
inv(16)(pl3q22) 
t(16; 16)(pl3; q22) 
RARa t(15; 17)(q22; q2l) 
t(11; 17)(q23; q2l) 
t(5; 17)(q32; q2l) 
t(11; 17)(ql3; q2l) 
der(17) 
t(3; 5)(q25; 1; q34) 
MLL t(6; 11)(q2l; q23) 
t(9; 11)(p22; q23) 
t(11; 22)(q23; qll) 
t(11; 17)(q23; q2l) 
t(10; 11)(pl2; q23) 
t(11; 19)(q23; pl3) 
t(1; 11)(q2l; q23) 
t(11; 19)(q23; q25) 
t(10; 11)(pll. 2; q23) 
t(11; 19)(q23; pl3) 
t(6; 11)(q27; q23) 
t(11; 22)(q23; ql3) 





t(7; 11)(pl5; pl5) 
t(1; 11)(q23; pl5) 
t(6; 9)(p23; q34) 
t(9; 22)(q34; qll) 
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The primary cytogenetic aberrations associated with AML may occur with other 
non-random, secondary chromosomal abnormalities. Such changes may be found 
in the same clone as the primary aberration, or in other side line clones. These 
abnormalities are thought to represent later genetic events, which may contribute 
to disease progression. A number of these secondary chromosomal abnormalities 
associate with particular primary aberrations; trisomy 8 is frequently associated 
with t(15; 17) and t(9; 22), loss of sex chromosomes or del(9q) frequently occur in 
association with t(8; 21) whilst trisomy 22 is associated with inv(16). Although the 
clinical and biological significance of these associations remains unknown in 
AML, the secondary cytogenetic changes associated with CML frequently predict 
for acceleration or impending blast crisis. 
Core Binding Factor (CBF) translocations 
Clinically, young adult patients with AML associated with core binding factor 
(CBF) rearrangements are highly responsive to remission induction therapy and 
high-dose cytarabine containing post-remission therapy. Complete remission 
rates of 80-90% and median disease-free survival in excess of 5 years are not 
uncommon (Bloomfield et al., 1998; Haferlach, 1996). The chromosomal 
aberrations associated with these responses include t(8; 21)(q22; q22), 
inv(16)(pl3q22) and t(16; 16)(p13; q22)- 
The t(8; 21)(q22; q22) translocation is found in approximately 10% of patients with 
de novo AML, and is strongly associated with M2 FAB subtype, the 
morphological features associated with this rearrangement include 
dysgranulopoiesis, eosinophilia, prominent Auer rods, and cytoplasmic 
vacuolation. The molecular consequence of t(8; 21) involve the disruption of 
AML1 gene on 21q22 and the ETO gene on 8q22, resulting in the formation of the 
AMN-ETO chimeric fusion gene on the derivative chromosome 8. The AML1 
gene codes for the a subunit of CBF, a heterodimeric transcription factor that 
binds to the enhancer core motif TGT/cGGT. Transcriptional regulation by 
AML1 is thought to regulate the expression of several myeloid and T-cell specific 
genes, including GM-CSF, M-CSF, IL-3, and the T-cell receptor cc, P, 'Y and 6 
subunits. The t(8; 21) translocation results in loss of aC terminal transcriptional 
activation domain on AML1 which results in differentiation block, and or 
leukaernic transformation of normal myeloid differentiation. Indeed knock-in 
murine embryos heterozygous for AML1-ETO have impaired foetal liver 
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haemopoiesis, and die in utero from severe CNS and soft tissue haemorrhage as a 
consequence of thrombocytopenia (Okuda et al., 1998). This suggests that AMLI- 
ETO fusion gene inhibits normal haemopoiesis through the dominant negative 
repression of AMLI mediated transcriptional activation. 
The inv(16)(pl3q22) and t(16; 16)(pl3; q22) chromosomal aberrations occur in 
approximately 8% of de novo AML cases and are strongly associated with AML 
M4EO. This FAB subtype is characterised by myeloblastic/monoblastic infiltration 
of the bone marrow, together with atypical eosinophil infiltration. The 
inv(16)/t(16; 16) results in the disruption of the 0 subunit of CBF at 16q22, and the 
smooth muscle myosin heavy chain gene at 16pI3. The inversion results in the 
formation of a chimeric CBFB-MYHll fusion gene, which dominantly represses 
CBF-mediated transcriptional activity, resulting in a block in myeloid cell 
differentiation. 
The RARa translocations and Acute Promyelocytic Leukaemia (APL) 
The t(15; 17)(q22; q21) translocation is specific to AML M3 and M3, which account 
for 7-10% of all AML cases. In association with above translocation, these FAB 
subtypes are characterised by high complete remission rates and prolonged 
disease-free survival if managed with curative therapy that includes all-trans 
retinoic acid (ATRA). The translocation disrupts the RARA and PML genes at 
17q21 and 15q22 respectively, resulting in PML-RARA and RARA-PML chimeric 
fusion genes. The RARA gene encodes RAR(x, a ligand activated nuclear 
transcription factor, and member of the retinoic acid receptor family (RARs). The 
retinoic acid receptor family consists of two distinct protein groups, the RARs 
and RXRs. These proteins form RAR-RXR heterodimers that bind to retinoid 
regulatory elements (RARE) on target genes. In the absence of specific ligand, the 
RAR-RXR heterodimer bind a nuclear protein (N-CoR) which induces gene 
repression through its interaction with other proteins, including histone 
deacetylase (HDAQ and Sin3. Under normal physiological conditions, specific 
ligand (retinoic acid) produces conformational change in the RAR-RXR complex 
with resultant dissociation of N-CoR/co-repressor complex, allowing 
recruitment of transcriptional coactivators and gene expression at RARE sites. 
Although it remains unclear how expression of PML-RARA chimeric protein 
leads to leukaemogenesis, it has been suggested that PML-RARA may interfere 
with RAR-RXR heterodimer formation in a dominant negative manner. This 
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inhibition can be overcome by pharmacological levels of retinoic acid in patients 
with the t(15; 17) translocation (Collins, 1998; Melnick and Licht 1999). 
A variant of APL, morphologically identical to AML (W), is characterised by a 
t(11; 17)(q23; q2l) translocation which results in the fusion of RARa to a gene at 
IIq23 termed promyelocytic leukaemia zinc finger (PLZF), with the formation of 
a chimeric protein PLZF-RARAa. PLZF-RARA(x forms a stable complex with N- 
CoR, which remains associated at pharmacological concentrations of ATRA. 
Thus PLZF-RARA(x APL, unlike PML-RARA(x APL, is unresponsive to ATRA 
and is characterised by a poor clinical outcome. 
1Iq23 translocations 
There are at least 30 translocations in acute leukaemia that involve 
rearrangement of Ilq23 (Table 1-4). Although IIq23 rearrangements have been 
documented in adult AML and ALL, the highest frequency is found in childhood 
leukaemia, particularly in infants where it accounts for 60-80% of cytogenetic 
aberrations (Rubnitz & Look, 1998). The 1Iq23 translocations frequently involve 
the disruption and in-frame fusion of the MLL gene (mixed lineage leukaemia 
gene) at IIq23, with distinct genes located at specific breakpoints on partner 
chromosomes. The MLL gene codes for a 4000 amino acid protein which contains 
several important functional domains including three adjacent "AT hooks" 
which bind DNA, a cysteine rich region which shares homology with DNA 
methyltransferase and a SET domain implicated in DNA repair and telomere 
function. The partner genes of MLL may determine leukaemic phenotype, for 
example, t(9; 11)(p22; q23), t(11; 19)(q23; pI3.1) and t(6; 11)(q27; q23) are associated 
with AML with M4/M5 FAB type, whereas t(4; 11)(q2l; q23) and 
t(11; 19)(q23; p13.3) are associated with ALL. 
The prognostic importance of 11q23 aberrations in AML is varied. In secondary 
AML associated with topoisomerase 11 exposure, 11q23 aberrations are associated 
with a poor outcome to therapy, whereas in de novo AML 11q23 translocations 
carry an intermediate risk (Grimwade et al., 1998). This variation in prognosis 
may partly reflect the inherent heterogeneity of 11q23 translocations, and the 
direct influence of MLL partner genes on disease biology. 
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t(9; 22)(q34; qll. 2) in de novo AML 
The t(9; 22)(q34; qll. 2) translocation occurs in over 90% of cases with CML, but 
occurs infrequently in de novo AML where only 2% of patients present with the 
Philadelphia chromosome. The translocation results in a fusion between the BCR 
gene at 22qI1.2 and ABL at 9q34. The resultant BCR-ABL chimeric gene encodes 
an activated tyrosine kinase, which leads to leukaemic transformation. 
Philadelphia positive AML commonly co-express myeloid and lymphoid marker 
antigens, and is associated with a poor outcome to chemotherapy. 
Chromosomal deletions in AML 
Structural chromosomal aberrations resulting in the deletion of genetic material 
occur in leukaemia and myelodysplasia. The loss of tumour suppressor genes in 
a number of non-random deletions is thought to be critical to the initiation of 
leukaemogenesis. In order to localise these genes investigators have defined 
consistently deleted regions in clinical material, and screened candidate genes in 
these regions for loss of heterozygosity using molecular based methods. 
Complete and partial deletions of chromosome 5 
Chromosomal deletions involving 5q-/-5 frequently occur in malignant myeloid 
disorders, and are especially prevalent in t(AML) arising as a result of radiation, 
or alkylating agent exposure. In this group of disorders, chromosome 5 deletions 
occur in up to 40% of cases (Pedersen-Bjergaard et al., 1990). Chromosome 5 
deletions also occur with increased frequency in the elderly, compared to 
younger patients with de novo AML (Leith et al., 1997). Acute myeloid leukaemia 
with these these cytogenetic aberrations are characterised by a poor prognosis, 
with low rates of complete remission and median survival times of less than 4 
months (Schiffer et al., 1989). Candidate tumour suppressor genes associated with 
5q-/-5 AML are thought to be located in region spanning 700bp at 5q31 
(Horrigan et al., 2000), at least 9 potential candidate genes are located at this 
locus. 
Complete and partial deletions of chromosome 
The complete and partial loss of chromosome 7 (7q-/-7) are the most 
frequent 
chromosomal aberrations associated with t(AML) and like 5q-/-5 aberrations, 
commonly occur in elderly AML patients. With current intensive chemotherapy, 
AML associated with monsomy 7, like monosomy 5, is characterised by a low CR 
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rate and poor disease-free survival (Grimwade et al., 1998; Swansbury et al., 
1994). Although a definitive tumour suppressor gene associated with loss of 
material from chromosome 7 in patients with myeloid malignancy has yet to be 
identified, chromosomal banding studies suggest that regions, 7q22 and 7q32-36 
may contain a possible tumour suppressor gene(s) (Dohner et al., 1998; Liang et 
al., 1998). 
Trisomies in AML 
Trisomy is commonly seen in AML, and other myeloid malignancies, either as a 
single chromosomal aberration, or in conjunction with primary cytogenetic 
aberrations, where the trisomy usually represents cytogenetic evolution of the 
primary clone. The most frequently observed numerical chromosomal aberration 
in AML is trisomy 8, which is associated with a intermediate prognosis 
(Grimwade et al., 1998; Schoch et al., 1997). However, some studies have 
documented an unfavourable prognosis in AML associated with trisomy 8 (Byrd 
et al., 1998). 
Presentation karyotype and clinical characteristics 
The overall frequency of recurrent chromosomal aberrations in AML does not 
differ between men and women (Mauritzson et al., 1998). However, a number of 
less common aberrations have been associated with sex of the patient, for 
example, idic(X)(ql3) in AML is found more frequently in females, whilst 
t(11; 19)(q23; pl3.3) is associated with male infants (Mrozek et al., 1997). 
Furthermore, if numerical aberrations involving sex chromosomes are ignored, 
an association between hyperdiploidy and male sex and hypodiploidy and 
female sex can be demostrated (Fourth International Workshop on Chromosomes 
in Leukaemia, 1984). 
A number of cytogenetic changes occur more frequently among different age 
groups. Structural rearrangements such as t(8; 21), inv(16), t(15; 17) commonly 
occur in patients less than 60 years, whilst numerical aberrations such as -5/5q-, - 
7/7q-, and complex aberrations have been found to occur preferentially in older 
patients with AML (Dastugue et al., 1995; Leith et al., 1997). Other chromosomal 
aberrations that have been reported to occur more frequently in the elderly 
include trisomy 8,11, and 13. 
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Clinical correlations between presentation karyotype and haematological 
parameters have been shown to exist. Acute myeloid leukaemia presenting with 
high leucocyte count may occur in association with rearrangement of 16q22, 
whilst relatively low leucocyte counts occur most frequently in association with 
t(15; 17). In addition, AML with t(15; 17) and t(8; 16) aberrations are often 
associated with coagulopathy (Barbui et al., 1998; Stark et al., 1995). The 
extramedullary presentation of AML occurs with increased frequency with 
specific karyotypic abnormalities, for example granulocytic sarcoma is associated 
with the t(8; 21) translocation, and may occur in up to 25% of patients with this 
cytogenetic aberration, whilst intracerebral myeloblastomas have been associated 
with M4EO and inv(16)(pl3q22) (Tallman et al., 1993; Vidal et al., 1999). 
Cytogenetics and AML morphology 
Although several associations between AML FAB type and specific recurrent 
chromosomal aberrations have been established, only two karyotypic 
abnormalities have a strong association with specific AML FAB subtypes. These 
chromosome rearrangements include t(15; 17) and its molecular equivalent PML- 
RARa which are found exclusively in AML M3/M3v only, and 16q22 which 
invariably associates with AML M4EO* 
A weaker association exists between t(8; 21) and AML M2. Although 90% of cases 
with t(8; 21) occur in association with AML M2, the t(8; 21) translocation accounts 
for one third of M2 cases with a karyotypic abnormality. If patients with a 
normal karyotype are included then the frequency of microscopically detectable 
t(8; 21) is nearer 17% (Fourth International Workshop on Chromosomes in 
Leukemia, 1984). However, if the molecular rearrangement of t(8; 21), namely 
AMM-ETO is screened for in patients with AML M2, it can be found in up to 25% 
of cases (Andrieu et al., 1996). Rearrangements of IIq frequently occur at 
breakpoint 11q23, and commonly associate with AML M5a. The numerical 
aberrations monosomy 5, monosomy 7, trisomy 8, trisomy 21, and AML 
associated with normal karyotype show no specific correlation with AML FAB 
types. 
Correlations exist between bone marrow morphology in AML, and presentation 
karyotype. For example, bone marrow eosinophilia (defined as ý! 5% bone 
marrow eosinophils) is associated with 16q22 rearrangements irrespective of 
whether the FAB type is M4EO, and to a lesser extent with t(8; 21). Bone marrow 
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basophilia is a common feature of AML with t(6; 9) or 12p deletion. The presence 
of Auer rods is associated with t(8; 21), t(15; 17), and t(9; 22) as well as complete or 
partial deletions of chromosomes 5 or 7, whilst the presence of 
micromegakaryocytes and trilineage dysplasia commonly occurs in de novo AML 
with abnormalities of 3q21 and 3q26. 
Patient karyotype: an independent prognostic factor in AML 
Presentation karyotype was shown to be an independent prognostic factor in 
AML for the first time in a multicentre prospective study reported by the Fourth 
International Chromosomes in Leukemia Workshop (Bloomfield et al., 1984). This 
study, which included 716 patients with newly diagnosed AML, of which 305 
received intensive induction chemotherapy, demonstrated that patients with a 
completely normal karyotype (NN) had a better overall survival than patients 
with a mixture of abnormal and normal metaphases (AN) or exclusively 
abnormal metaphases (AA). There was no significant difference in overall 
survival between AN and AA patients. These findings were substantiated in a 
follow up study in 1989 (Arthur et al., 1989), which demonstrated that patient 
karyotype remained an independent prognostic factor in predicting clinical 
outcome when patient age, FAB type and sex were also considered in 
multivariate analysis. This study also demonstrated that patients with a complex 
karyotype had a poor overall survival. Other studies, using different 
classification criteria for patient karyotype, have also demonstrated that 
presentation karyotype is an independent prognostic determinant for complete 
remission, remission duration and overall survival (Grimwade et al., 1998; Stasi et 
al., 1996). 
Complete remission rates 
The clinical studies in AML where cytogenetic data has correlated with outcome 
have typically involved younger patients. In the majority of these studies, the 
highest rates of complete remission, typically (80-98%), where attained in 
patients with t(8; 21) or inv(16)/t(16; 16) (Bloomfield et al., 1984; Grimwade et al., 
1998). Less favourable CR rates have been associated with complete and partial 
deletions of chromosome 5, and 7 as well as complex karyotype (40-67%). 
However, although the partial deletion of chromosome 7 (7q-) is commonly 
associated with low CR rates, relatively high CR rates have been observed in 
some series (Grimwade et al., 1998), suggesting that 7q- may be a cytogenetic 
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marker of standard risk. 
Following the use of ATRA, AML M3 characterised by the t(15; 17) translocation 
has been associated with favourable CR rates of nearly 90%. In contrast, patients 
with AML M3 and the t(11; 17) (characterised by the fusion of PLZF and RARa 
genes), have low rates of CR irrespective of whether all-trans-retinoic acid is used 
as part of induction therapy (Licht et al., 1995). 
The complete remission rates associated with structural rearrangements affecting 
IIq23 have varied between series (Mrozek et al., 1997) and may reflect differences 
in induction therapy, size of the patient cohort, and or the heterogeneity of the 
translocations, for example adults with t(9; 11)(q22; q23) have better CR rates than 
adult patients with other 11q23 translocations (79% vs 57%) (Mrozek et al., 1997). 
Duration of remission 
The duration of remission in AML often correlates with the cytogenetic 
aberrations present at the time of diagnosis. Thus patients with t(8; 21), inv(16), 
and t(15; 17) have the highest probability of remaining in CR at five years. By way 
of contrast patients with complex karyotype, monosomy 7, and complete or 
partial loss of chromosome 5 are characterised by a high relapse risk (Grimwade 
et al., 1998). 
Overall survival 
Superior overall survival in adult patients with AML have been associated with 
t(8; 21), 16q22 rearrangements and t(15; 17), with five year survivals ranging from 
50-70% in some studies (Bloomfield et al., 1998; Grimwade et al., 1998; Mrozek et 
al., 1997). Interestingly although a favourable outcome is associated with 
t(8; 21) translocation a subset of patients with granulocytic sarcoma and t(8; 21) 
have a relatively poor outcome (Byrd et al., 1995). Likewise in children, AML 
associated with t(8; 21) confers a standard or poor prognosis (Martinez-Climent et 
al., 1995). 
In contrast to the chromosomal aberrations associated with favourable outcome, 
cytogenetic aberrations repeatedly associated with poor survival included 
rearrangements of 3q2l, -5/5q-, -7, and complex karyotype (Grimwade et al., 
1998; Leith et al., 1997). 
The prognostic significance of cytogenetic data and indeed other prognostic 
factors are in part dependent upon the treatment protocols used to treat AML. 
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Clearly the advent of ATRA therapy in AML M3, has resulted in a significant 
improvement in CR and overall survival for patients with this subtype of AML. 
Whilst favourable outcome associated with AML characterised by 
rearrangements involving CBF partly reflect their sensitivity to high dose 
cytarabine containing regimens (Bloomfield et al., 1998). Thus cytogenetic 
aberrations currently predictive of unfavourable outcome may in the future 
predict for standard or favourable prognosis if significant improvements in 
therapy can be found. Furthermore, by uncovering novel cryptic aberration it 
may be possible to obtain important prognostic data that influence clinical 
management. This principle has been clearly illustrated in childhood leukaemia 
with the discovery of the cryptic t(12; 21)(p13; q22) translocation resulting in 
TELIAMLI fusion. Children with this translocation are characterised by an age 
between 1 and 10 years, B-lineage ALL and an extremely good prognosis with 
standard curative therapy (Faderl et al., 1998; Shurtleff et al., 1995). 
At the present time cytogenetic data allows for a risk-adapted approach to 
therapy in AML. For example, young AML patients with 'unfavourable' 
cytogenetic abnormalities unlikely to benefit form standard induction regimens 
are often treated with 'high-risk' experimental protocols in an attempt to improve 
CR and survival. Similarly, patients with 'favourable' karyotype may not 
necessarily require (or be offered) consolidation with high dose chemotherapy 
and stem cell rescue in first CR, due to the superior results achieved with 
consolidation regimens containing high-dose cytarabine 
'Minimal residual disease' 
At the time of presentation patients with acute leukaemia may have up to 10" 
leukaemic blasts. However, as a consequence of the limited resolution of 
morphological analysis, which at best may detect up to 1 leukaemic cell in 100, 
significant residual leukaemic infiltration (IO'cells) may still persist in patients 
who are considered to be in complete remission, which may ultimately lead to 
relapse. 
Assays used to detect minimal residual disease (MRD) rely upon the ability to 
detect leukaemic cells using a variety of techniques including, cytogenetic and 
molecular cytogenetic analysis, immunophenotyping and cell growth 
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characteristics. Minimal residual disease detection using conventional 
cytogenetic techniques allows the detection of leukaemia based upon the 
chromosomal aberrations present at the time of diagnosis. The detection of 
abnormal clones after therapy may predict relapse (Burnett et al., 1999), although 
the failure to detect abnormal clones does not necessarily preclude the possibility 
of relapse. Similarly, the attainment of a complete or major cytogenetic response 
in CML (<35%, t(9; 22) +ve metaphases) equate with an improved long term 
survival in patients (Kantarjian et al., 1996). Molecular cytogenetic techniques 
such as FISH, and the molecular detection of gene rearrangements using 
polymerase chain reaction (PCR) have further refined MRD detection in 
leukaernia (Campana & Pui, 1995). In AML the aim of therapy in patients with 
AML M3 is the establishment of PCR negativity for PML-RARa. Patients who are 
persistently positive for the transcript after the completion of therapy have a 
higher rate of relapse (Campana & Pui, 1995). In the case of t(8; 21) AML a 
number of studies have reported positive reverse transcriptase-PCR results in 
patients in long term remission (Burnett et al., 1999). However, at least one 
multicentre study has demonstrated a correlation between PCR negative results 
for AML-ETO after induction therapy, and absence of relapse (Morschhauser et 
al., 2000). 
The Scope of This Thesis 
Acute myeloid leukaemia primarily occurs in individuals 60 years or older. 
However, the results from clinical trials frequently reflect outcome in younger 
patients due to patient selection. Thus clinical outcome data from many trials 
may not be applicable to elderly adults with AML. 
Prognostic factors such as presentation karyotype influence therapeutic decision 
making in AML. Furthermore, new molecular cytogenetic technologies capable 
of refining cytogenetic analysis now exist. In this thesis, the therapeutic 
management of AML in patients 60 years or older at a single centre will be 
reviewed and analysed in order to provide a historical overview of the disease in 
the elderly. Factors influencing clinical outcome in this group will also be 
examined, along with cytogenetic data. This will include an appraisal of two new 
FISH technologies, namely CGH and M-FISH in order to determine the relevance 
of these techniques in elderly patients with AML. 
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Chapter 2 
Introduction 
The distinct pathophysiology of AML in older patients frequently results in poor 
outcome in those patients in whom aggressive curative therapy is attempted. Thus 
for many physicians the decision to treat an elderly patient with AML using 
intensive chemotherapy is often controversial. Frequently, clinical criteria and the 
perceived ability to withstand aggressive chemotherapy, are the limiting factors 
when curative therapy is contemplated in older patients with the disease. 
It can be argued that factors predictive of clinical outcome should be used to direct 
therapeutic decisions in AML regardless of age. However, clinical studies limited to 
elderly patients with AML are uncommon. Thus it can be deduced that prognostic 
factors which influence clinical outcome in older patients with the disease have been 
poorly investigated and under utilised. 
Aims of this Analysis 
In Western Europe and North America AML is predominantly a disease of the 
elderly (age>60years) with a median age at the time of presentation of 64 years 
(Brinker, 1982; Cartwright et al., 1997). Unfortunately many elderly patients are 
excluded from clinical trials due to strict entry criteria, and or patient or physician 
bias (Hutchins et al., 1999; UKCCCR, 2000). Thus the results of clinical trials in AML 
can not be readily extrapolated to older patients, many of whom are characterised by 
poor clinical outcome due to patient and disease-related factors such as presentation 
karyotype (Hiddemann et al., 1999; Lowenberg, 1996). In addition, whilst prognostic 
factors are often taken into consideration when treating younger patients, they are 
seldom utilised in elderly patients, who are frequently selected for curative 
treatment on clinical grounds rather than objective criteria that may influence 
treatment outcome. 
Over a thirty year period, 420 consecutive adults (age>60 years) with AML were 
referred to the ICRF Medical Oncology Unit at St Bartholomew's Hospital for 
management. This represents a cohort of patients treated at a single centre during 
the era in which the modern chemotherapeutic management of AML began, and 
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subsequently evolved, in unison with important advances in supportive care. In 
order to evaluate the impact of supportive care and intensive chemotherapý- in a 
historic setting, a retrospective analysis of the clinical outcome data from elderly 
patients with AML treated at St Bartholomew's Hospital over a thirty year period 
will be performed. The analysis will include the analysis of cytogenetic data for a 
subgroup of elderly patients who were successfully karyotyped. This data will be 
presented in relation to clinical outcome so that the prognostic importance of 
presentation karyotype in older patients can be evaluated, 
Patients and Methods 
Patients 
Four hundred and twenty consecuti\-e adults (age>60 years) with newly diagnosed 
AML were managed at St Bartholomew's Hospital between June 1969 and December 
1999 (the notes of 192 patients were reviewed retrospectively in order to obtain 
additional clinical information not recorded at the time of diagnosis). A total of 288 
patients (69%) received combination chemotherapy with curative intent. Patients 
were selected for treatment based on clinical grounds and individual patient wishes. 
The clinical details of patients included in the study are shown in Table 2-1. 
Cytogenetic analysis 
Cytogenetic analysis was introduced for newly diagnosed patients with AML in 
1987. Standard cytogenetic analysis was performed in the Medical Oncology Unit 
using bone marrow or peripheral blood from patients at the 
time of diagnosis. Short term cultures were established using complete medium 
(RPMI 1640 with glutamax, 20% fetal calf serum, 1% Streptomycin and Penicillin). 
Metaphase preparations were harvested, and GTG banding performed 
(Czepulkowski et al., 1992). Patient karyotypes were described according to the 
International System For Human Cytogenetic Nomenclature (ISCN) (NEtelman, 
1995). 
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Table 2-1 











Median 66 70 67 <0.01 
Range 60-83 60-86 60-86 
Sex M: F 170: 118 74: 58 244: 176 0.72 
Blast count (xlO'/I) 
Median 4.5 1.0 3.2 0.003 
Range 0-329 0-389 0-389 
Hb (g / dl) 
Median 9.0 8.6 8.9 0.64 
Range 3.2-16.5 4-17.6 3.2-17.6 
WBC (xlO'/I) 
Median 12.2 5.4 10.1 0.01 
Range 0.3-350 0.5-475 0.3-475 
Platelets (x109/1) 
Median 47 50 47 0.55 
Range 5-658 7-398 5-658 
Serum LDH (IU/1) 
Median 560 2964 560 0.18 
Range 210-5658 451-4750 210-5658 
Albumin (g/1) 
Median 37 35 36.5 <0.001 
Range 24-49 22-44 22-49 
FAB MO 1 2 3 
Mi 99 27 126 
M2 81 30 
M3 8 3 
M4 58 25 83 0.001 
M5 24 4 28 
M6 12 5 17 
M7 1 4 5 
Hypoplastic AML 4 15 19 
Antecedent 
haematological 47 23 70 0.63 
disorder 
Hepatomegaly alone 27 16 43 
Splenomegaly alone 19 2 21 
0.13 
Hepatosplenomegaly 31 9 40 
Neither 114 46 160 
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Treatment regimens 
Between 1969 and 1999 six generations of combination chemotherapy based on an 
anthracycline/anthracendione in combination with cytarabine were investigated in 
adult patients with AML 60 years of age or older, 18/420 patients received treatment 
with alternative regimens; details of all these therapies are included in Table 2-2. 
From 1969 to 1972, patients over 60 years of age received identical chemotherapy to 
younger adults, whilst between July 1972 and 1978, older patients were treated in a 
separate program (Barts IVb). At the beginning of the Barts IX trial, all adults with 
AML received the same combination chemotherapy until the introduction of 
mitoxantrone and cytarabine in July 1987. The first 26 patients received 
mitoxantrone 12 Mg/M2 intravenously for 3 days and cytarabine at 100 Mg/M2 twice 
daily intravenously, for 7 days. Due to a high early recurrence rate, the remaining 49 
patients received mitoxantrone 10 Mg/M2 intravenously for 5 days, with the same 
dose and schedule for cytarabine (MacCallum et al., 1995). The aim was to 
administer a total of 4 cycles of treatment irrespective of the number of cycles 
required to achieve complete remission. 
Supportive care 
The antibiotic regimens used to treat neutropenic fever evolved over the three 
decade period to reflect a greater emphasis on gram negative cover provided by first 
line antibiotics. From 1969 to 1978, patients with neutropenic fever were initially 
treated with ampicillin and flucloxacillin, whilst aminoglycoside and broad- 
spectrum cephalosporin antibiotic combinations were introduced as first line 
therapy thereafter. Patients treated on the Barts IX trial were prescribed non- 
absorbable prophylactic antibiotics in the form of TRACON' (framycetin, colistin 
and nystatin) for gastro-intestinal decontamination. Although G-CSF and GM-CSF 
became commercially available in the early 1990's, these colony-stimulating factors 
were not routinely used as an adjunct to the management of neutropenic fever in 
elderly patients. Red cell products were initially available in the form of fresh blood, 
and later as packed cells. Between 1969 and1971, platelet support was 
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Table 2-2 
Details of the intensive treatment regimes 
Trial/Drugs Daily dose /M2 Days Year Number of patients 
Barts 1& 111 1969-1972 21 
Daunorubicin 55mg iv 1 
Cytarabine 70mg iv 1-5 
Barts 11 1970-1971 5 
Daunorubicin 55mg iv 6 
Cytarabine 140mg iv 1-2 
70mg iv 6 
Barts IVb 1972-1978 62 
Danorubicin 55mg iv l+3 
Cytarabine loomg iv 1-5 
Barts IX 1978-1980 15 
Adriamycin 50mg iv 1 
Cytarabine 10Omg bd iv 1-5 
6-Thioguanine 10Omg bd oral 1-5 
Barts X 1978-1980 26 
Adriamycin 25mg iv 1-3 
Cytarabine 10Omg bd iv 1-7 
6-Thioguanine 10Omg bd oral 1-5 
Barts XI 1981-1983 21 
m-Amsacrine 10Omg iv 1-5 
Cytarabine 10Omg bd iv 1-7 
'3+7' 1983-1986 45 
Adriamycin 25mg iv 1-3 
Cytarabine 10Omg bd iv 1-7 
Mitoxantrone/cytarabine 
Nfitoxantrone 10mg iv 
or 
12mg iv 
Cytarabine 100mg bd iv 
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provided in the form of fresh blood, whilst pooled and single donor Platelets were 
used between 1972 and 1974 and from 1974 onwards, respectively. Prophylactic 
platelet and red cell transfusions were administered to maintain counts above 
10xlO'/l and IOg/dl respectively. 
Def initions 
The morphological diagnosis of AML was made according to the French American 
British classification of acute leukaemia (Bennett et al., 1976; Bennett et al., 1985a; 
Bennett et al., 1985b; Bennett et al., 1991). The presence of coexisting trilineage 
myelodysplasia with de novo AML was determined according to recognised criteria 
(Brito-Babapaulle et al., 1987). Complete remission (CR) was defined as patients 
being well, in the presence of a normocellular bone marrow containing less than 5% 
blast cells, together with peripheral blood counts demonstrating Hb>10g/dl,, 
neutrophils>IxIO9/1 and platelets>100 xIO'/l. 
Patients were classified as having "resistant disease' (RD) if there was either no 
change or an increase in the percentage of leukaemic blast cell infiltration at the time 
of evaluation after one or two cycles of treatment. Patients who did not achieve CR 
because of a hypocellular bone marrow or peripheral blood cytopenia, despite the 
absence of leukaernic bone marrow infiltration were also included in this group. 
Deaths attributable to organ failure, infection or bleeding during the first two cycles 
of chemotherapy, in the absence of resistant disease were defined as treatment- 
related deaths (TRD) 
Statistical methods 
Potential prognostic markers for survival were assessed using a logrank test, with 
multivariate analysis performed using Cox regression. For achievement of CR, the 
same factors were assessed using logistic regression. The comparatively small 
number of patients with resistant disease made the derivation of a multivariable 
prognostic model for this outcome unfeasible. Therefore, univariate analysis was 
used to analyse potential factors for resistant disease. For categorical variables, this 
was performed using Fisher's exact test, whilst a Mann-Whitney test was used to 
investigate the equality of the distributions of continuous measurements between 
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patients with and without resistant disease. Analyses of all cytogenetic data tables 
were performed by exact or monte-carlo methods. The natural ordering of all 
ordered categorical variables (eg age group) was preserved by using an "exact" 
version of the Kruskal Wallis test (for singly-ordered tables) or the jonckheere- 




Comparisons between the sex of the patient, haemoglobin, platelet count, serum 
LDH, antecedent haematological disorder and abdominal organomegaly revealed no 
significant difference for the two patient groups (Table 2-1). Patients receiving 
treatment with curative intent had a statistically significant lower median age, and 
higher median white count, blast count and serum albumin compared to those 
managed conservatively. The frequency of FAB types was also significantly different 
between the two groups, although the three most frequent FAB types overall in 
decreasing order were MI, M2 and M4. 
Cytogenetics 
From July 1987 to December 1999 mitoxantrone/cytarabine was the regimen used to 
treat elderly patients with curative intent. This coincided with the introduction of 
routine cytogenetic analysis for all new cases of acute leukaernia. The cytogenetic 
data for patients eligible for treatment with mitoxantrone/cytarabine is presented 
below. 
Cytogenetic analysis 
Cytogenetic analysis was performed using bone marrow or peripheral blood from 
108/124 patients who were eligible for treatment with mitoxantrone/cytarabine. 
Informative cytogenetic results were obtained in 95% of cases, normal karyotype 
was noted in 44% of patients with informative results, and was the commonest 
karyotype noted in patients who received chemotherapy with curative intent (49%), 
whilst normal karyotype accounted for 34% in patients who were managed 
conservatively. 
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Modal Number 
Pseudodiploidy was found in 18 patients (17%). Twenty two cases were hypodiploid 
(21%): of these, 14 had 45 chromosomes, 6 cases had 44 chromosomes, and the 
remaining two cases had 43 and 42 chromosomes respectively. In most patients with 
45 chromosomes hypodiploidy was the result of monosomy 7 (n=7) or monosomy 5 
(n=5). 
Numerical chromosomal aberrations 
The most frequent numerical aberrations included monosomy 5, monosomy 7 and 
trisomy 8 (Figure 2.1). Monosomy 7 was noted in 9% of patients, and was the sole 
abnormality in 3%. The remaining cases had a complex karyotype that included 
monsomy 5 and other numerical aberrations as well as structural rearrangements. 
Abnormalities resulting in complete or partial deletion of chromosome 5 were 
associated with complex karyotype, and occurred in 10% and 7% of patients 
respectively. An extra copy of chromosome 8 was observed in 9% of patients, and 
was the sole abnormality in 6%. The acquisition of an extra copy of chromosome 21 
occurred in 4% cases and in 3/4 of these cases, was associated with other 
chromosomal aberrations. 
Recurrent chromosomal translocations 
Non-random translocations normally associated with de novo AML were less 
frequent than numerical aberrations; [t(8; 21) 3%, t(15; 17) 3%, inv(16) 2%]. In the three 
patients with the t(8; 21)(q22; q22) translocation, one case was pseudodiploid, the 
remaining two cases had 47 and 45 chromosomes as a result of trisomy 8 and loss of 
the Y chromosome respectively. The t(15; 17)(q22; q2l) translocation was found in 3 
cases, one had an extra copy of chromosome 8. The inv(16)(pl3q22) rearrangement 
was noted in two patients, both of which were pseudodiploid. 
Presentation karyotype and prognostic subgroups 
For the purposes of clinical outcome patients were divided into 3 cytogenetic 
subgroups retrospectively based upon previously defined MRC prognostic criteria 
(Grimwade et al., 1998): [1] 'favourable' ft(8; 21), t(15; 17), inv(16)], [2] "unfavourable/ 
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chromosomal rearrangements)], [3] 'intermediate' [other chromosomal 
abnormalities (miscellaneous) and normal karyotypel (Tables 2-3 & 2-4). 
Considering only those patients with informative results, presentation 
karyotypes consistent with an "intermediate' prognosis were the most frequent 
prognostic subgroup in patients who received treatment with curative intent, 
accounting for 75% of informative cytogenetic results. 'Unfavourable' 
chromosomal aberrations were the second most frequent cytogenetic subgroup in 
patients managed with curative intent accounting for 14%, whilst "favourable' 
karyotype accounted for 11% of informative results in this group of patients. 
When patients who were managed conservatively were considered, 
'unfavourable" aberrations accounted for 42% of informative results. Presentation 
karyotypes associated with 'intermediate" prognosis accounted for 55% of 
informative results in this group, with normal and miscellaneous karyotypes at 
34% and 21% respectively, whilst 'favourable" karyotype occurred in only 3%. 
The distribution of prognostic subgroups between the two patient cohorts was 
statistically different (p=0.003) with patients receiving curative therapy having 
significantly more favourable karyotypes than patients who were managed 
conservatively. 
Cytogenetic subgroup and patient age 
When patients were stratified according to age, chromosomal aberrations 
associated with 'intermediate' prognosis were the commonest chromosomal 
aberrations in each age group (Table 2-5). "Favourable' karyotypes were the least 
frequent subgroup overall, accounting for 11% in patients 60-65 years old and 66- 
70 years old. Interestingly, 'favourable" cytogenetic aberrations were not noted in 
patients over 70 years of age. There was a trend toward an increase in the 
frequency of 'unfavourable" cytogenetic aberrations with increasing age. For 
patients aged 60-65 years old, 'unfavourable-' cytogenetics aberrations were noted 
in 19% of patients and 43% of patients over 76 years old. By comparison, the 
frequency of partial deletion of chromosome 5, and monosomy 7 showed no 
discernible relationship with patient age (Table 2-6). Although the total numbers 
were small, when the specific chromosomal aberrations associated with poor 
outcome were grouped together there was a trend toward an increase in the 
frequency of these aberrations with increasing age. The total number of 
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Table 2-3 
Abnormal presentation karyotypes for AML patients eligible for treatment with 
mitoxantrone/cytarabine 
Favourable n=8 
46, XY, t(8; 21) 
47, XY, +8/46, XY, t(15; 17) 
45, X, -Y, t(8; 21) 
46, XX, inv(16) 
46, XXt(15; 17) 
47, XY, t(8; 21), +8 
46, XY, inv(16) 
46, XY, t(15; 17) 
Unfavourable n=25 
47, XX, +X, del(l)(pl3), -5, der(7), +der(7), 
+8, +9, add(10)(q2? ), -11, -18,20, add(22)(ql3), +mar [cplO] 
45, XY, -7 
50, XY, +5, +8,16q+, +19, +21/46, XY 
44-45, XX, -2, -3, -5, -7, add(ll)(pl5), -14, -17, -21, -22, +5-9mar [cp] 
80-86, chromosomes with evolution of the above clone 
45, XY, -5, -18, +marl, del(3p)/44, XY, -5, 
-7,18, +marl, del(3p), +3q, deII2(pl2),? +17p/45, XY, -5, -7, -18, +marl, 
? +mar2, del(3p), +3q, del(12)(pl2)/46, XY 
44, XY, -4, -5, der (7), t (7;? ) (ql 1 . 2;? 
), 
-8, -8, -16, -20, +marl, +mar2, +mar3, +mar4/46, XY 
44, XY, t(1; 17)(pl3; pl? ), -3, 
del(5)(q22; q34), add(6)(p2? ), der(7)t(3; 7)(q2l; q36),? 8, 
der(9), t(6; 9)(p2l; p22-23), -12, -13, +2mar 
45, XY, -7 
44, XX, -4, add(5)(qll. 2), t(12; 16)(ql3; ql2), add(15)(qll. 2), -17, -18, +marl46, idem, +add(5)(qll. 
2), +lI 
45, XY, -5, add(7)(p22), del(12)(pl2) 
43, XY, der(3), -5, add(8)(q24), -17, add(17), -18, -20, +mar, +r 
45, XY, -7, +mar 
45, XY, -7 
47, XX, -5, +. mar(l), +mar(2)/48, XX, -5, 
-16, +20, +C, +mar(3), +mar(4)/46, 
XX, -14, +mar(5) 
45, XY, r(3), -5, -17, +mar2/45, idem, del(12)(pl? )/45, XY, r(3), 
-5, -17, +mar3/46, XY, de1(3)(pl?; p2? 
), -5, -7, +marl, +mar2/46, XY 
47, XX, del(20)(qll. 2), +del(20)(qll. 2)/48, idem, +8/47, idem, 
del(5)(q32) 
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45, XX, -7, add(8)(q24) / 48, idem, +4, +12, +22 
46, XX, der(5)t(1; 5)(q2l; q2l), add(19)(pl3)/46, XX, dup(l)(q2l; q4? )/ 
46, XX 
44, XY, t(11; 22)(ql3; ql3), r(3), +10p, +16p, -5, -6, 
-7, +r/43, XY, t(11; 22)(ql3; ql3), r(3), +10p, +16p, -5, -6, -7/46, XY 
42, X, -Y, del(5)(ql3; q35), dic(12; 16)(pll. 2; qll.? ), 
-18, dic(19; 20)(pl3.3; ql 1.1) /43, idem, +dic(19; 20)(pl3.3; ql 1 -1) /61, X, 
-Y, +l, +l, +2, +3, +5, del(5)(ql2; q35), +6, +8, +8, +10, +13, +14, +14, +19, 
add(19)(pl3.3), +21, +2mar (composite karyotype) 
76-81, XXYY, -2, -2, add(2)(pl? ), -3, -6, -7, -8, add(8)(q2? ), -9, -9, 
-10, add(Il)(q2? ), add(ll)(q2? ), -13, -14, -15, -16, -17, -22, +4-9mar 
46, XY, del(5)(qll. 2q33 orql3; q35), dic(7; 17)(qll. 2; pll. 2), +8, 
-12, add(22)(ql3), +mar/47, idem, -marl, +mar2, +mar3/46, XY 
45, XY, -5, add(9)(pl3), del(ll)(q23; q25), -13, der(15; 17)(qlO; qlO), 
del(20)(qll. 2; q13.3), add(21)(q22), +der(? )t(13;? )(ql2;? ), +mar/45, XY, 
-5, add(9)(pl3)del(ll)(q23; q25), der(15; 17)(qlO; qlO), add(16)(q22), 
del(200(qll. 2; ql3.3), add(21)9q22), +mar/45, XY, -5, add(8)9q24), 
add(9)(pl3), del(ll)(q23; q25), der(15; 17)(qlO; qlO), add(16)(q22), 
del(20)9qll. 2; ql3.3), add(21)(q22), +mar 
44, XY, -2, -3, der(4)t(2; 4)(ql; pl5), -5, add(7)(qll. 2), t(7; 15)(p22; ql), 
del(12)(pll. 2pl3), -20, der(20)t(3; 20)(p2l; ql3.3), +mar, +r/46, XY 
44, XX, add(5)(ql), dic(6; 22)(pll; pl2), der(7)t(6; 7)(pll; q22), 
idic(ll)(pll), -12, -17, +mar[10] 
Miscellaneous n=25 
45, XX, -9, i(17)(qlO)/46, XX 
47, X'Y, +21 
46, XY, del(17)(pl2)/46, XY 
47, XX, +8 
47, XY, +8/46, XY 
47, XY, +ll 
46, XY, t(9; 11)(p22; q23) 
46, XY, del(9)9ql3; q22)/46, XY 
47, XY, +8 
47, Y, XX 
46, XY, dup(l)(p22; p3? 6)/46, XY, dup(l)(p22; p3? 6), dup(l)(p22; p3? 6)/ 
46, XY 
46, XY, add(10)(q2)/46, XY 
47, XY, +21/46, XY, add(14)(q32) 
47, XY, +13/46, XY 
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46, XY, t(12; 17)(pl2; pl3) 
47, XY, +8/46, XY 
47, XY, +13 
46, XY, t(12; 13)(q24; ql4), del(9)(ql2)/46, XY 
47, XY, +8/46, XY 
45, XY, der(14; 15)(qlO; qlO) /46, XY 
46, XX,? del(12)(pl2)inc/46, XX 
46, XY, i(7)(plO) 
47, XX, +8 
46, XY, add(21)(q2) 
45, X, -Y, -9, +mar/45, X, -Y 
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Table 2-4 
Cytogenetic prognostic subgroup at presentation: Comparison between elderly patients 
receiving curative therapy and elderly patients treated conservatively. 
Prognostic group Curative Conservative Total 
chemotherapy treatment 
nNnNn 
Favourable"' 7 (11) 1 (3) 8 
Unfavourable" 9 (14) 16 (42) 25 
Intermediate' 49 (75) 21 (55) 70 
(Normal) 32 (49) 13 (34) 45 
(MiscellaneouS2) 17 (26) 8 (21) 25 
Total 65 38 103 
Key 'Favourable' group: t(8; 2 1), t(I 5; 17), inv(1 6) 
'Unfavourable' group: -5/5q-, -7, complex karyotype (3 or more 
distinct chromosomal 
rearrangements) 
'Intermediate' group: other chromosomal abnormalities (miscellaneous) and normal 
karyotype 
'Distribution of cytogenetic subgroups (favourable, unfavourable and intermediate) 
between the two patient groups p=0.003 
2 Distribution of cytogenetic subgroups (favourable, unfavourable miscellaneous and 
normal) between the two patient groups p=0.01 
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cytogenetic anomalies associated with each abnormal karyotype varied 
significantly with regard to patient age (p=0.02). 
Younger patients were more likely to have presentation karyotypes with I or 2 
distinct abnormalities, whilst older patients had a tendency to present with three 
or more cytogenetic aberrations. Thus there was a significant correlation between 
complex karyotype and increasing age. 
Clinical outcome 
Complete remission 
An evaluable outcome was noted in 287/288 patients who received 
chemotherapy with curative intent. Complete remission was achieved in 88 
patients, representing a CR rate of 31%, (but a real CR rate of only 21% if the 
entire patient cohort is considered). When reviewed by era, CR rates increased 
with each chronological change in remission induction chemotherapy, (with the 
exception of the period between 1981 and 1983), rising from 13% between 1969 
and 1972 to 45% in the era 1987 and 1999 (Table 2-7). Similarly, when patients 
were analysed on an 'intention-to-treat' basis, CR rates within each era again 
increased, (with the exception of patients treated with Barts Xl) from 10% in the 
period 1969-1972 to 28% between 1987 and 1999. Overall, CR was achieved with 
the first cycle of chemotherapy in 55% of patients. Seventy six percent of patients 
treated with mitoxantrone/cytarabine achieved CR with the first cycle of 
chemotherapy, compared to 29% and 27% for patients treated between 1983 
and1987 and 1978 and 1980 respectively. 
Factors associated with achievement of CR on univariate analysis included initial 
chemotherapy received, serum albumin, and hepatosplenomegaly (p=0.01, 
p=0.01 and p=0.02 respectively) (Table 2-8). When patients receiving 
mitoxantrone/cytarabine were considered in isolation, factors associated with 
achievement of CR on univariate analysis included, presentation karyotype, 
serum lactate dehydrogenase (LDH), and presence of hepatosplenomegaly. 
Patients with "favourable" and normal karyotype had a significantly higher CR 
rate compared to patients with 'unfavourable" karyotype (71% v 22%; p=0.05), 
and (46% v 22%; p=0.04) respectively. Serum LDH was routinely measured at the 
time of presentation from 1990, and was available on 44 patients who received 
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mitoxantrone/cytarabine. For these patients, the median serum LDH for patients 
in whom CR was achieved was 559 IU/I (normal range 240-480 IU/I) compared 
to 755 IU/I in patients in whom treatment failed. Patients with LDH<twice upper 
limit of normal (n=32) had a significantly higher CR rate compared to patients 
with LDH>twice upper limit of normal (n=12) (86% v 14%; p=0.04). Likewise 
patients without hepatosplenomegaly (n=52) had a significantly better CR rate 
than patients with hepatosplenomegaly (n=10) (52% v 10%; p=0.01). 
On multivariate analysis factors predictive of reduced CR included treatment era 
(1969-1972,1972-1978,1978-1980), and hepatosplenomegaly (Table 2-8), whilst for 
patients treated with mitoxantrone/cytarabine, age (increment) was the only 
factor that correlated with a decreased probability of achieving CR (p=0.01). 
Although patients with serum LDH>twice upper limit of normal illustrated a 
trend towards reduced CR, it was not a statistically significant association. In 
addition, "unfavourable" karyotype was weakly predictive of a reduced 
probability of achieving CR when serum LDH was excluded from multivariate 
analysis. 
Disease-free survival 
The median disease-free survival (DFS) for all remitters (n=88) was 10 months 
(range 3 weeks-22 years). There was no significant difference between the 
duration of DFS and the era in which patients were treated, although patients 
treated in the period between 1969 and 1972, and 1972 to 1978 were noted to 
have 
the shortest DFS at 4 and 7.5 months respectively (Figure 
2.2). Statistical analysis 
failed to identify any association between DFS and clinical or 
laboratory 
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Table 2-6 
Karyotypic patterns and specific chromosomal aberrations in AML in relation to age 
Age (years) 
60-65 66-70 71-75 >76 
n=37 n=35 n=24 n=7 
(36%) (34%) (23%) (7%) p-value 
n (%) n (%) n (%) n M 
Normal 12 (32) 16 (46) 15 (62) 2 (29) 
Abnormal 25 (68) 19 (54) 9 (38) 5 (71) 0.10 
1 anomaly 15 (40) 10 (28) 4 (17) 1 (14) 
2 anomalies 5 (14) 1 (3) 1 (4) 0 0 )0.02 
ý3 anomalies 5 (14) 8 (23) 4 (17) 4 (57) 
t(8; 21) 1 (3) 2 (5) 00000.71 
t(15; 17) 2 (5) 1 (3) 00000.30 
inv(16) 1 (3) 1 (3) 00000.67 
Total 4 (11) 4 (11) 0000 
-5 2 (5) 5 (14) 3 
(13) 0 0 0.60 
5q- 1 (3) 3 (9) 1 (4) 2 (29) 0.14 
-7 4 (11) 1 
(3) 3 (13) 1 (14) 0.84 
7q- 1 (3) 3 (9) 0 0 1 (14) 0.74 
3q 1 (3) 0 0 0 0 0 0 0.43 
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Table 2-8 









Multivariate analysis OR 95% confidence 
interval 
Treatment era (base line 1987-1999) 
1969-1972" 0.17 0.05-0.53 0.002 
1972-1978' 0.41 0.21-0.83 0.01 
1978-1980 0.44 0.19-0.99 0.05 
Hepatosplenomegaly 0.26 0.09-0.75 0.01 
*Age (5 year increment) 0.14 0.03-0.57 0.01 
Cytogenetic sub-group' 
(base line: Normal) 
'Unfavourable' 0.17 0.02-0.97 0.06 
'Favourable' 1.33 0.20-8.61 0.77 
Nfisceflaneous 0.35 0.08-1.46 0.15 
Key: 
OR= odds ratio (ratio<lreduced probability of CR with presence of the term) 
'Multivariate analysis on an intention to treat basis [treatment era 1969-1972 OR=0.28, p=0.02; 
1972-1978 OR=0.48, p=0.02] 
Tatients treated with mitoxantrone/cytarabiine 
t multivariate analysis on mitoxantrone/cytarabine patients if LDH excluded 
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Treatment-related death and resistant disease 
When the complications associated with remission induction chemotherapy were 
considered, treatment-related deaths accounted for treatment failure in 50% of 
patients treated overall (Table 2-7). Reviewed by era, TRD declined appreciably 
from 84% between 1969 and 1972, to 27% for the period between 1987 and 1999, 
(with the exception of early deaths associated with Barts XI) 
Severe infection during the period of bone marrow aplasia remained the major 
cause of TRD for patients over the thirty year period, accounting for 55% of TRD 
overall. Between 1969 and 1978, approximately 30-40% of TRD were attributable 
to infection, this figure increased to approximately 70-90% in trials conducted 
between 1978 and 1999. The introduction of non-absorbable antibiotics for 
prophylactic gastro-intestinal tract decontamination in patients treated with Barts 
IX was not associated with a reduction in TRD due to infection. Deaths 
attributable to haernorrhage accounted for 20% of TRD between 1969 and 1978, 
falling to less than 10% thereafter, reflecting better haemostatic support by the 
provision of prophylactic platelet concentrates. 
Resistant disease was noted in 20% of patients who received chemotherapy with 
curative intent between 1969 and 1999 (Table 2-7). However, treatment failure 
due to RD increased four-fold from 6% in the period between 1972 and 1978, 
rising to approximately 26% thereafter, despite an improvement in CR rate. This 
trend was probably attributable to improvements in supportive care, and the 
subsequent reduction in treatment-related death rate amongst patients with AML 
resistant to chemotherapy. For patients who received mitoxantrone/cytarabine, 
resistant disease occurred more frequently in patients with "unfavourable' 
karyotype (44%) than in any other cytogenetic subgroup. Patients with 
'favourable' karyotype who received chemotherapy did not demonstrate disease 
resistance at all, whilst patients with normal karyotype and miscellaneous 
cytogenetic aberrations had similar rates of resistant disease at 19% and 18%, 
respectively. These differences were not statistically significant. Furthermore 
statistical analysis failed to identify any clinical or laboratory factors associated 
with RD. 
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Figure 2.2 
Duration of remission of elderly ANIL patients by treatment era 
1987-1999 N= 37 
1983-1986 N= 14 
1981-1983 N= 5 
1978-1980 N= 11 
1972-1978 N= 17 




Chapter TWO : AML in the elderly, St Bartholomew's Hospital (1969-1999) 
Survival 
With a median follow-up of 11 years, actuarial survival for all patients at 1,3 and 
5 years was 20%, 7% and 4% respectively, whilst median survival from time of 
diagnosis was 2 months (Figure 2.3). For patients who were treated with curative 
intent, patients in whom CR was achieved had a significantly better median 
survival than patients in whom treatment failed (14 months V6 months; 
p<0.00001). Not surprisingly, the overall survival (OS) of patients who received 
treatment with curative intent was significantly better than that of patients who 
were managed conservatively (3 months vI month; p=0.0001). 
Long term survival (greater than 5 years) was noted in 13 patients. Informative 
cytogenetics were available in 9/13 at the time of diagnosis; ('favourable, n=41 
normal n=4, miscellaneous n=1). Two patients who were in first remission 
relapsed at 8 months ("favourable" karyotype), and 2 years (normal karyotype) 
respectively, and subsequently entered second remission having received further 
chemotherapy. These two patients are currently alive and disease-free at 7 and 12 
years respectively. Of the remaining 11 patients, 4 
are alive in first CR (favourable' n=2, normal n= 1). The remaining 7 patients died 
in first CR. 
Factors associated with survival by univariate analysis included initial treatment 
received, age, serum albumin, and hepatomegaly (Table 2-9). For patients treated 
with mitoxantrone/cytarabine, factors correlating with OS on univariate analysis 
included presentation karyotype and serum LDH- Patients in the "favourable' 
and 'intermediate' cytogenetic subgroups had better OS compared to patients in 
the 'unfavourable' subgroup (10 months vI month, p=0.04), (6 months vI 
month, p=0.03) respectively. Patients in the 'favourable' subgroup also had a 
better OS than patients in the 'intermediate' subgroup (p=0.05), whilst the OS of 
patients with a normal karyotype, and miscellaneous chromosomal aberrations 
were similar. In addition, the median survival of patients with serum LDH<twice 
upper limit of normal was significantly better than that of patients with an serum 
LDH>twice upper limit of normal (10 months v 1.25 months; p<0.002). 
Several clinical and laboratory factors retained predictive value for OS on 
multivariate analysis (Table 2-9). Curative therapy between 1969 and 
1983 
predicted for reduced OS, whilst the presence of hepatosplenomegaly also 
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Table 2-9 
Factors associated with overall for elderly patients with AML treated with curative intent (1969-1999) 
p-value 
Univariate analysis 
Treatment era 0.001 
Age 0.01 
Serum albumin <0.001 Hepatosplenomegaly 0.004 
Multivariate analysis HR 95% confidence 
interval 
White blood count 1.06 1.03-1.08 <0.001 
Platelet count 0.82 0.73-0.92 0.001 
FAB type 
mi 1.48 1.18-1.87 0.001 
M3 1.93 0.99-3.74 0.05 
Hepatosplenomegaly 1.72 1.13-2.61 0.01 
Treatment era (base hne 1987-1999 
1969-1972 2.07 1.42-3.00 <0.01 
1972-1978 1.67 1.26-2.21 <0.01 
1981-1983 1.64 1.11-2.43 0.01 
*LDH 3.29 1.38-7.86 0.01 
(>twice upper limit of norrnalý 
*Age (5 yea increment) 1.84 1.15-2.95 0.01 
*Cytogenetic sub-group 
'Unfavourable' 3.58 1.24-10.3 0.02 
'Favourable' 0.29 0.06-1.46 0.13 
Miscellaneous 1.04 0.48-2.28 0.92 
Key: HR= hazard ratio (ratios>1 predict for reduced overall survival). 
Tatients treated with n-dtoxantrone/cytarabine 
-'Serum LDH normal range: 240-4801U/I 
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predicted for reduced OS. A number of haematological parameters were found to 
be predictive of reduced OS, and included raised white blood count, and MI and 
M3 FAB types. Interestingly, normal platelet count at presentation was predictive 
of better OS. For patients treated with mitoxantrone/cytarabine, both raised 
serum LDH and 'unfavourable' karyotype remained predictive of reduced OS, 
but in addition to these factors, increasing age was also found to predict for 
reduced OS (Table 2-9). 
Time in hospital (in-patient stay) 
For patients managed conservatively, the median days in hospital was 2 weeks, 
compared to 6 weeks in those managed with curative intent. This reflected the 
time required for haemopoietic recovery after chemotherapy. It was not possible 
to accurately record recovery times for neutrophils and platelets in the majority 
of patients who received chemotherapy. However, for patients who received 
mitoxantrone/cytarabine, the median time to recovery of neutrophils>0.5xl09/1 
was 25 days and did not differ significantly in relation to the number of cycles of 
mitoxantrone/cytarabine received, whilst the median time to recover 
platelets>50x109/1 was 22 days. Importantly, only 15% of patients who received 
mitoxantrone/cytarabine were fit enough to receive two or three courses of 
chemotherapy, whilst only 4% received the desired 4 courses of therapy due to 
the significant morbidity and mortality associated with the treatment. These data 
illustrate the difficulty in delivering consecutive courses of chemotherapy to 
elderly patients and tentatively suggest that this was not due to excessive 
haematological toxicity. 
In order to measure quality of life in the absence of a performance status score, it 
was assumed that patients receiving therapy in hospital had a worse quality of 
life relative to patients discharged home. The median days in hospital relative to 
OS for patients managed conservatively and patients managed with curative 
therapy was 82% and 51% respectively, this difference was not significantly 
different (p=0.74). Thus there was no difference in this quality life measure for 
the two patient cohorts. 
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Discussion 
Although AML is predominantly a disease that occurs in adults over 60 years of 
age, the majority of published clinical data pertain to selected patients below 60 
years of age. Thus clinical trial data often reflects a 'best case scenario' (view) 
which can not readily be extrapolated to elderly adults. Many older patients 
selected for treatment with curative intent experience significant morbidity and 
mortality, with reduced remission rates and survival compared to younger 
patients treated similarly. Consequently it is commonly assumed that all elderly 
patients have a poor clinical outcome. In this study the cytogenetic and clinical 
data for elderly AML patients treated at a single centre over thirty year period 
were presented. 
Although the total number of patients in the study at 420 was sizeable it was only 
possible to analyse cytogenetic data for patients referred between 1987 and 1999, 
as cytogenetic analysis for patients with acute leukaemia was routinely available 
from 1987. Analysis of the cytogenetic data confirmed that the majority of elderly 
patients with AML had an abnormal karyotype, although the number presenting 
with normal karyotype was appreciable (44%). In the group as whole, 
informative cytogenetic results were obtained in 95% of cases analysed and 
abnormal karyotype was documented in 56%. This figure is similar to that 
reported by the MRC, which noted an abnormal karyotype in 58% of patients 
with AML below 56 years of age (Grimwade et al., 1998). In two studies in which 
cytogenetic aberrations were documented specifically in elderly patients, 
abnormal karyotype was noted in 55% and 42% of patients respectively (Baudard 
et al., 1994; Leith et al., 1997). Thus although some authors suggest that abnormal 
karyotype can be detected in up to 80-90% of patients with AML using 
conventional banding methods (Yunis et al., 1981), for older patients, the results 
from this study and others would suggest that abnormal karyotype is detected 
less frequently. 
In those patients who presented with an abnormal karyotype the majority were 
found to have numerical aberrations. Although patients were not selected for 
treatment with curative intent on the basis of presentation karyotype, the 
distribution of cytogenetic aberration as defined by prognostic subgroup was 
found to differ significantly between patients managed conservatively and 
patients managed with curative intent. The most striking difference was the 
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higher frequency of -unfavourable' aberrations in patients managed 
conservatively at 42%, compared to 14% in patients managed with curative 
intent. 'Favourable' cytogenetic aberrations were the least frequent chromosomal 
aberrations in both groups. However, 11% of patients managed with curative 
intent had a 'favourable' karyotype compared to only 3% in patients managed 
conservatively. 
Numerical aberrations particularly monosomy 5, monosomy 7, and trisomy 8 
were the most frequent aberrations noted, whilst the non-random chromosomal 
rearrangements, t(8; 21), t(15; 17) and inv(16) occurred infrequently. Numerous 
studies have documented a relationship between patient age and the incidence of 
specific aberrations, with 'unfavourable' aberrations occurring more frequently 
in older patients and 'favourable' aberrations occurring more frequently in 
younger adults (Baudard et al., 1994; Fenaux et al., 1989; Fourth international 
Workshop on Chromosomes in Leukaemia, 1984; Taylor et al., 1995). Whilst 
determining the incidence of chromosomal aberrations in young adults with 
AML was not an aim in this study, there was a significant trend towards an 
increase in the incidence of " unfavourab le "-complex karyotypes with increasing 
age amongst the patients analysed. 
Between 1969 and 1999,420 patients were eligible for treatment with curative 
intent. One hundred and thirty two patients (31%) were deemed unsuitable for 
intensive chemotherapy due to severe co-morbid disease, poor general condition 
or the patient declined treatment. This figure is concordant with most series 
(Anstrom. et al., 2000; Baudard et al., 1994; Ferrara et al., 1998b). Thus, the above 0 
data illustrates the first major clinical problem in the management of AML in 
older patients ie, a significant number of elderly adults are unsuitable for 
curative therapy at the time of diagnosis. The clinical outcome for these patients 
is extremely poor, and in this study those patients managed conservatively were 
characterised by a median survival of only 4 weeks. 
For patients treated with curative intent, the overall CR rate was 31%. 
However, 
the correct interpretation of the CR data should take into account those patients 
excluded from curative treatment. Thus considering all patients, 
CR was 
achieved in only 88/420 patients (21%). Therefore, in reality, 
CR was achieved in 
a minority of elderly patients. Furthermore, the 
CR rate in this study was 
approximately half that quoted in published series 
in which elderly patients 
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ineligible for intensive chemotherapy are excluded from analysis (Leith et al., 
1997; Liu Yin et al., 1991; Lowenberg et al., 1998; Lowenberg et al., 1989). Despite 
these disappointing figures a meaningful improvement in CR was documented 
over a thirty year period, with CR rates increasing significantly from 13% to 45% 
in treated patients. 
Another significant problem encountered when managing AML in elderly 
patients is the inability to deliver consecutive courses of chemotherapy to those 
in whom achieve CR is achieved. As a direct consequence of treatment related 
morbidity and mortality, only 4% of patients who received 
mitoxantrone/cytarabine went onto receive the desired 4 courses of 
chemotherapy. Thus the median DFS of 10 months documented in this study 
probably reflects the clinical consequence of this phenomenon. Furthermore, the 
similarity in DFS associated with each era was probably a function of reduced 
intensity of treatment and an ability to deliver more courses of chemotherapy in 
earlier eras, coupled with an increased intensity and the inability to deliver 
sequential courses of chemotherapy in later eras. However, this can only be an 
assumption given the inability to clearly document the number of courses of 
consolidation chemotherapy administered in each era. 
Several clinical /biological factors were found to influence CR on multivariate 
analysis. The less intensive regimens in use between 1969 and 1980 were 
associated with a lower probability of achieving CR. However, on an 'intention- 
to-treat' basis,, only regimens used for curative therapy between 1969 and 1978 
remained predictive on multivariate analysis (Table 2-8). The presence of 
hepatosplenomegaly also correlated with a lower probability of achieving CR. 
By analysing patients who received mitoxantrone/cytarabine separately, it was 
possible to assess the impact on CR of a number of biological factors which were 
not available for analysis in earlier eras, namely presentation 
karyotype, and 
serum LDH. For these patients, increasing age was the only factor predictive of a 
lower probability of achieving CR, whilst 'unfavourable' karyotype was weakly 
predictive of reduced CR rate when serum LDH was not 
included in the 
multivariate analysis. Although "unfavourable' karyotype was 
identified as an 
independent factor predictive of a decreased likelihood of achieving 
CR for older 
patients in a recent study (Leith et al., 1997), it 
is important to note that the 
authors grouped 'favourable' and 'intermediate" 
karyotypes together for the 
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purposes of statistical analysis. The cytogenetic subgroups were considered 
separately for the purposes of this study, despite the relatively low number of 
patients in each subgroup of patients. 
By comparing clinical outcome according to era, it was not only possible to 
confirm that intensification of therapy, coupled with improved supportive care 
led to an increase in the CR rate, and a dramatic reduction in TRD. Of note, 
patients treated between 1981-83 with Barts XI experienced a relatively high TRD 
rate with only a modest CR rate of 23% compared to other regimens. Indeed 
Dhaliwal and co-workers reported excessive toxicity amongst older patients who 
received this regimen, with a particularly high rate of gastrointestinal and 
hepatic toxicity (Dhaliwal et al., 1986). Considering all patients who received 
treatment with curative intent, TRD occurred in 50% overall, although the TRD 
rate in the era between 1987-1999 was only 27%. Importantly, despite the 
availability of broad-spectrum antibiotics and antifungal agents TRD due to 
severe infection remained the most frequent cause of treatment failure amongst 
elderly patients receiving remission induction therapy. 
The relatively high rate of TRD associated with treatment of AML in the elderly 
has led some authors to advocate dose attenuation as a way of reducing 
treatment-related mortality (Manoharan, 1998). However, recent trials have 
clearly shown that older patients receiving intensive therapy have a better CR 
and OS, without significantly increased mortality (Buchner et al., 1995; Rees et al., 
1996). Thus although the delivery of supportive care to patients receiving 
treatment with curative intent is of paramount importance, the rapid 
achievement of CR also makes an essential contribution to the reduction in TRD 
rate (Hiddemann et al., 1999). Therefore, the fact that CR was achieved in 76% of 
patients with the first cycle of mitoxantrone/cytarabine, may have contributed to 
the reduction in TRD in this cohort, compared to earlier regimens. 
The OS of patients within this study was in keeping with other reported series in 
that it was disappointingly low. The majority of patients died within 1 year of 
diagnosis, and only 4% of patients were alive 5 years from diagnosis. 
Multivariate analysis identified laboratory and clinical factors predictive of 
OS, 
including the presence of hepatosplenornegaly, and treatment era (1969-1983), 
both of which predicted for reduced OS. A number of 
haematological indices 
were also similarly predictive of reduced OS, including raised white 
blood count, 
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and MI and M3 FAB types. It is important to emphasise that although M3 FAB 
type is strongly associated with the t(15; 17) translocation, which predicts for 
favourable outcome, ATRA was not included in the curative regimens for elderly 
patients who presented with AML M3. It was interesting to note that normal 
platelet count predicted for better OS despite the provision of platelet 
concentrates from 1972. 
For patients who received mitoxantrone/cytarabine as curative therapy, 
'unfavourable" karyotype, serum LDH>twice upper limit of normal and 
increasing age were all predictive of a significantly poorer OS by multivariate 
analysis (Table 2-8). These findings are in keeping with similar studies in older 
patients with AML (A nstrom et al., 2000; Ferrara & Mirto, 1996; Leith et al., 1997). 
The decision to treat elderly patients should take into consideration quality of life 
issues as well as prognostic factors that independently influence patient outcome. 
An objective assessment of quality of life was only possible retrospectively, and 
required the assumption that quality of life was better for those patients who 
spent time at home rather than in hospital. Patients treated with curative intent 
had a lower median number of days in hospital as a percentage of OS, although 
this did not reach statistical significance, suggesting that quality of life was 
similar for patients in the two treatment groups. 
For patients treated with curative intent, the prognostic data obtained in this 
study clearly demonstrated that patient age and treatment era predict for two 
measurable outcomes namely CR and OS, whilst serum LDH and cytogenetic 
subgroup predicted for OS. Prognostic factors identified in other studies include 
multi-drug resistance phenotype, antecedent haematological disorder and 
performance status at the time of presentation (Baudard et al., 1994; 
Johnson et al., 
1995; Leith et al., 1997). Although it was not possible to assess the impact of 
multi-drug resistance phenotype and performance status on clinical outcome, 
in 
this study antecedent haematological disorder was not 
found to be predictive of 
CR or OS. 
Prognostic models based upon the results of multivariate analysis can 
be used to 
stratify patients and thus bring objectivity to the therapeutic 
decision making 
process. For example, performance status, peripheral 
blood count, hepatomegaly 
and blood urea can be used in a model to predict survival 
in older patients with 
AML (Johnson et al., 1995). Similarly, other authors have reported 
the successful 
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use of serum LDH and presentation karyotype as a way of objectively selecting 
patients for aggressive chemotherapy (Ferrara et al., 1998b). The development 
and validation of a prognostic scoring system was not an aim of this study. 
However, given the potential problems that face the older patient, and their 
physicians when curative treatment is administered, such scoring systems should 
be developed and evaluated in future studies. 
Summary 
The results of this study revealed that although 69% of patients received 
treatment with curative intent, CR occurred in a minority of patients (21%). 
Importantly CR rate increased in the three decades studied, whilst ED declined. 
These findings were attributable to more intensive therapy, and better supportive 
care. Prognostic factors associated with treatment outcome included patient age, 
treatment era, serum LDH, and "unfavourable' karyotype. By utilising these 
factors, it may be possible to direct curative therapy to older patients with AML 
more appropriately. 
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Chapter 3 
Background 
The cytogenetic study of leukaernia has led to a better understanding of 
leukaernogenesis and to a 'molecular' appreciation of leukaernia biology. Clinical 
AML studies incorporating cytogenetic data have also highlighted the prognostic 
importance of chromosomal aberrations in AML. These two aspects of AML 
cytogenetics were summarised in the previous chapter. 
Since routine cytogenetic analysis of AML became commonplace in the early 
1970"s banding analysis have yielded the most reliable assessment of patient 
karyotype. With the introduction of FISH based techniques, it has been possible 
to achieve chromosomal analysis at the molecular level with a higher detection 
sensitivity than can be achieved with conventional methods. Thus new molecular 
cytogenetic FISH techniques complement conventional banding methods and 
offer the ability to detect cryptic aberrations. Comparative genomic hybridisation 
(CGH) originally described in 1992 (Kallioniemi et al., 1992) is a relatively new 
molecular cytogenetic technique which allows the detection of amplification and 
deletion of genetic material from tumour specimens, without the need for cell 
culture. Unlike conventional FISH, it is possible to screen the entire genome for 
DNA copy number change in a single hybridisation step by using CGH. The 
technique can also be applied to frozen, or fixed tumour tissues, so in theory 
large tissue banks can be screened retrospectively using this technique. 
The primary clonal aberrations associated with AML in older patients tend to 
result in numerical change, with complete or partial loss of chromosome 5 or 7 
being the commonest abnormalities detected using conventional methods. This 
suggests that CGH may be an appropriate technique that could 
be exploited in 
the preliminary screening for oncogenes and tumour suppressor genes 
in elderly 
patients with AML. 
68 
Chapter Two : AML in the elderly, St Bartholomew's Hospital (1969-1999) 
Comparative Genomic Hybridisation: Studies in Haematological 
Malignancy 
Over the past seven years there have been at least fifteen studies in which CGH 
has been utilised in the cytogenetic study of leukaemia (Table 3-1). Bentz and co- 
workers were the first to document concordance between DNA copy number 
change and conventional banding results in a series of cases (8 AML, 2 MDS), 
and suggested that AML was a model tumour for the evaluation of CGH 
methodologies (Bentz et al., 1995). In subsequent studies in which AML was 
studied, CGH provided important additional cytogenetic information. 
Comparative genomic hybridisation was used in the cytogenetic analysis of a 
patient with AML with complex karyotype, and was able to provide information 
not provided by G-banded analysis (Nacheva et al., 1995). In a study of 25 adult 
patients with refractory AML, CGH detected interstitial deletions in 6 patients 
with complex karyotype in which complete monosomies had been identified 
using banding analysis (El-Rifai et al., 1997). In a another study CGH correctly 
localised aberrations poorly defined by banding techniques (Wilkens et al., 1998). 
By utilising CGH with other molecular cytogenetic techniques the karyotypic 
abnormalities associated with the human AML cell line GF-D8 has been possible 
including the identification of two regions associated with amplifications namely: 
8q2.3-qter and llq2l-qter (Tosi et al., 1999). Comparative genomic hybridisation 
was successfully applied in a case of AML M3 with double minutes, and made it 
possible to localise an amplified region to 8q24, implicating the MYC oncogene 
(Mohamed et al., 1993). In a similar case, CGH was used to localise regions of 
amplification in a case of AML to llq23-ýqter and 9pil-4pter, enabling the 
identification of the amplified genes by using Southern blot (Crosen et al., 1999). 
In acute lymphoblastic leukaemia (ALL) conventional banding analysis 
frequently produces poor quality chromosomes, especially in cases with complex 
karyotype. This may partly explain the lower rates of success for cytogenetic 
analysis in ALL compared to AML, (86% v 92%, UK NEQAS 1998-1999). 
Thus 
CGH studies in ALL have often yielded complementary data to 
banding analysis, 
particularly in cases with hyperdiploid ALL. Consequently, a number of authors 
have advocated the routine use of CGH in the routine 
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Table 3-1 Comparative genomic hybridisation studies in haernatological malignancy 
Study Disease Gains Losses Comments 
Mohanuned 1993 AML 8q24(MYQ 
Bentz 1995 AML/MDS 
Nacheva 1995 AML 




EI-Rafai 1997 AML 8q 
Karhu 1997 CLL 12 
Rodley 1997 CML 13q3l 
lq, 5p, 6p, 16q 
9q3l-->9q34 
Cigudosa 1998 Myeloma 19,19P 




Wilkens 1998 Haematological 
malignancy 
Wong 1998 ALL 
Crosen 1999 AML llq23->llq24 
9p 
Huhuta 1999 AML (paediatric) 
Su 1999 CML +8, +7, +17 
20,17q 
l(ql2-21qter) 
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cytogenetic analysis of childhood leukaernia (Larramendy et al., 1998b; Paszek- 
Vigier et al., 1997; Rice et al., 2000). 
The cytogenetic aberrations in CML that accompany acceleration or blast crisis 
frequently result in the acquistion of multiple copies of the Philadelphia 
chromosome, isochromosome 17q, and trisomy 8 and 19. CGH analysis of CML 
in accelerated phase or blast crisis has confirmed DNA copy number change in a 
number of cases, and documented a novel region of amplification I(ql2-21qter) 
thought to be involved in transformation, in at least 3 patients (Su et al., 1998). 
Until recently the routine cytogenetic analysis of multiple myeloma at the time of 
presentation was carried out infrequently. Recent reports suggest that karyotypic 
aberrations in multiple myeloma, like in AML, may predict for clinical 
responsiveness and severity of the disease. For example, the partial deletion of 
chromosome 13, (13q14) has been shown to correlate with the increased 
proliferative activity of myeloma, and predicts for a poor prognosis (Zojer et al., 
2000). In two studies in which CGH was utilised in the cytogenetic study of 
myeloma, CGH resulted in a higher rate of detection of karyotypic aberrations 
compared to conventional banding analysis (Avet-Loiseau et al., 1997; Cigudosa 
et al., 1998). In addition both studies confirmed that complete and partial deletion 
of chromosome 13 was the most frequent cytogenetic aberration in the cases of 
myeloma studied. 
Comparative genomic hybridisation has mainly been exploited in the cytogenetic 
analysis of solid tumours primarily because the technique does not require a 
source of dividing tumour cells. However, the reports cited in Table 3-1 clearly 
illustrate that CGH can also provide useful additive cytogenetic data when 
applied to haematological malignancy. 
Principles of Comparative Genomic Hybridisation 
Comparative genomic hybridisation requires the simultaneous 
in situ 
hybridisation of differentially labelled total tumour DNA (Spectrum 
Green) and 
normal DNA (Spectrum Red), in equal proportion, to normal 
human 
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Figure 3.1 
Spectrum Red 
control DNA, -ý, 
Cot-I DNA 




Schematic illustration of comparative genomic hybdridisation. Step[l] Spectrum Green 
labelled tumour DNA (test DNA) and Spectrum Red labelled normal (control DNA) are 
hybridised simultaneously with Cot-I DNA to non-nal human metaphase chromosomes. 
Step[2] images of the metaphase preparations are captured using a fluorescence microscope 
fitted with a CCD camera. Step[3] image analysis using dedicated software. Amplification 
or polysomy for chromosomes/ regions present in the tumour results in more intense 
green fluorescence at that site on the target chromosome due to excess copies in the 
tumour compared to control DNA. Likewise deletions or monosomies existing in the 
tumour will be highlighted by more intense red fluorescence since control DNA will 
preferentially hybridise. 
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metaphase chromosome preparations, under conditions of repeat sequence 
suppression (Figure 3.1). The chromosomal location at which under or over 
representation of tumour DNA sequence map was identified by an imbalance 
between green and red fluorescence ratio. By using a DNA counter stain, the 
metaphase chromosomes are banded, and therefore the sites of DNA copy 
number change can be assigned to chromosome a band region. 
The routine successful application of CGH relies upon several critical steps in the 
protocol: i. Metaphase chromosome preparation 
ii Isolation of high molecular weight DNA from tumour 
iii Image acquisition. 
Metaphase Chromosome Preparation 
Normal human metaphase chromosomes serve as the hybridisation targets for 
tumour /reference DNA probes in CGH, and as a result the quality of the 
metaphase spreads are critical to the successful application of CGH. The 
chromosomes used for CGH are prepared according to routine procedures from 
PHA stimulated peripheral blood lymphocytes. Optimal CGH metaphase 
spreads have a minimal number of overlapping chromosomes, and are of an 
adequate length for accurate fluorescence ratio measurements. The preparations 
should also be devoid of cytoplasm, which if present prevent satisfactory 
denaturation. Chromosomes should also retain their morphology after 
denaturation in order to allow accurate karyotyping and chromosome band 
identification (Karhu et al., 1997a). 
Tumour DNA isolation and Labelling 
In order to obtain an accurate CGH profile, DNA extracted from the tumour in 
question must be of high molecular weight, and ideally be derived from a high 
percentage of tumour cells, (60% or more) (Kallioniemi et al., 1994). Clearly this 
may not be possible in cases of acute leukaemia, since the morphological 
diagnosis of AML is achieved when the bone marrow is infiltrated by leukaemic 
blast cells which need only be as little as 30% (Bennett et al., 1976). 
Once total genomic DNA is extracted, tumour and reference DNA are 
labelled 
directly with different fluorochrome-conjugated nucleotides by nick translation 
to achieve probe fragment lengths of between 300-3000 
bp, which is considered 
optimal for hybridisation. 
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Image Acquisition 
Digital images from at least five high quality metaphase preparations are 
routinely captured using a fluorescence microscope fitted with a single bandpass 
filter set, and a charge coupled device camera (CCD). The CCD is made from 
silicon, and functions as a 'photon-detector'. When a CCD is exposed to photons 
generated by an excited fluorochrome, an electron potential is generated and 
propagated within its structure, proportional to the incident photons. The 
electron potential is then converted into a digital signal which can then be 
interpreted (Aikens et al., 1989; Hiraoka et al., 1987). 
Aims of this Study 
The description of non-random chromosomal aberrations in leukaemia is the 
initial step that hopefully leads to the identification of oncogenes and or tumour 
suppressor genes, which drive leukaemogenesis and influence disease biology. 
Historically this has relied upon conventional banding analysis, which in older 
patients with AML, demonstrate an increased frequency of numerical 
aberrations. 
CGH is a FISH based method, which can identify DNA copy number change 
throughout the genome, and can be used to screen tumour DNA for 
amplifications and deletions. The elderly (age> 60 years) define the largest group 
of patients with AML. In this group of patients the biology of the disease is 
distinct from AML in younger patients, partly as a consequence of specific 
chromosomal aberrations which occur with increasing frequency with age. Thus 
far, there have been no CGH studies in which DNA from a cohort of elderly 
patients has been screened for DNA copy number change. Therefore, the initial 
aim of this study is an appraisal of CGH in elderly patients with AML in order to 
determine whether or not the technique can provide reliable cytogenetic data, 
concordant with conventional analysis. Archival leukaemic blast cells from 
patients aged 60 years or more, will be used as the source of DNA. 
Conventional cytogenetic analysis requires in vitro cell culture, which may 
introduce selection bias towards a particular clone of cells. CGH analysis 
provides an 'average' DNA copy number karyotype, based upon the proportion 
of clones present in a tumour sample at the time it was taken from the patient. 
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Thus the second aim of this study is to determine whether CGH can provide 
additional cytogenetic information compared to G-banded analysis in elderly 
AML patients with either normal or abnormal karyotype, and to determine the 
prognostic significance of any additional cytogenetic data found. 
Patients and Methods 
Patient material 
Between 1985 and 1999,202 patients (aged>60 years) with newly diagnosed acute 
myeloid leukaemia (AML) had bone marrow or peripheral blood sent for 
cytogenetic analysis at St Bartholomew's Hospital. Fifteen patients were selected 
as having presentation archival material available for analysis. Bone marrow or 
peripheral blood mononuclear cells were collected from patients at the time of 
diagnosis, and stored at -70'C until they were used. The clinical laboratory data 
of the patients are listed in Table 3-2. 
Conventional Cytogenetic Analysis 
Standard cytogenetic analysis was performed by clinical cytogeneticists in the 
Department of Medical Oncology using bone marrow or peripheral blood from 
patients at the time of diagnosis. Short term cultures were established using 
complete medium (RPMI 1640 with glutamax, 20% fetal calf serum, 1% 
Streptomycin and Penicillin). Metaphase preparations were harvested, and GTG 
banding performed (Czepulkowski et al., 1992). Patient karyotypes were 
described according to the ISCN (Mitelman, 1995), and were later compared with 
CGH DNA copy number change profiles of patients analysed in the CGH study. 
Preparation of genomic DNA 
Archival bone marrow /peripheral blood mononuclear cells from elderly patients 
with AML (age>60 years) stored at -70'C were retrieved and thawed quickly, 
but 
gently, at 37'C in a water bath. The cells were transferred 
to a sterile culture 
vessel and 10ml of culture medium (RPMI 1640/ 
10% FCS) added slowly. The 
cells were washed twice and resuspended in Iml culture 
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Table 3-2 
Clinical and laboratory characteristics of patients included in the CGH study 
Patient Age Year Sex FAB BM Source [DNA] Karyotype 
of Of pg/p, diagnosis DNA 
01 69 1998 F mi 54 BM 2.3 A 
02 67 1998 m M4 73 BM 1.8 A 
03 60 1998 m M4 46 BM 1.5 A 
. 04 64 1995 F 70 PB 1.0 A 
05 71 1995 m mi 70 BM 0.5 A 
06 60 1998 F M2 54 BM 0.4 A 
07 75 1985 F mi 95 BM 0.3 N 
08 60 1996 m - BM 0.6 N 
09 68 1996 F mi 97 BM 0.7 N 
10 64 1983 F mi 85 BM 3.2 N 
11 62 1983 m M2 45 BM 1.2 N 
12 73 1994 F M4 90 PB 0.5 N 
13 68 1997 F M4 90 BM 0.9 N 
14 69 1985 F mi 90 BM 0.06 N 
15 67 1989 F M5 90 BM 0.8 N 
Key A=Abnormal karyotype, N=Normal karyotype 
. Secondary AML (Myelofibrosis->AML) 
BM= bone marrow 
PB= peripheral blood 
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medium. Viable cells were counted in a haernocytometer using trypan blue dye 
exclusion. 
The cell suspension was added to 2ml DNA digestion buffer 50-Pl. Proteinase K 
(O. Img/ml) were added and incubated overnight at 55'C for 18 hours. The lysate 
was then extracted with equal volumes of phenol, phenol/ chloroform and 
chloroform to remove denatured proteins. DNA was precipitated with 1/10" 
(original) volume 3M sodium acetate followed by 2x (original) volume 100% 
ethanol, recovered by centrifugation in an eppendorf centrifuge for 10min at 
14000 rpm. The DNA was washed in 70% ethanol, and left to dissolve overnight 
in distilled water. 
Estimation of DNA concentration 
The optical density (OD) of the solutions was measured relative to water at a 
wavelength of 280nm on a Pharmacia Biotech Gene Quant 11 spectrophotometer. 
In order to check the purity of DNA the OD at 280nm was measured. A ratio 
OD260/OD280 of 1.7-1.95 indicated a protein free sample. In addition, DNA 
quantitation was estimated visually by running DNA on a 1% agarose gel 
alongside a standard of known concentration. 
Agarose gel electrophoresis 
Gels were prepared by heating agarose in IxTris/borate/EDTA (TBE) 
electrophoresis buffer until completely resuspended to a final concentration of 
1% w/v. They were cast at 4'C using 8x6 cm mini gel trays containing 
appropriate sized combs, and submerged under 1xTBE. DNA samples, and a1 
Kb DNA ladder (298-12,216 bp) were mixed with 1/6' volume of 6x loading 
buffer (40%w/v sucrose, 0.2% w/v bromophenol blue) and loaded into wells. 
Gels were run at between 0.5-10 V/cm. The gels were stained with ethidium 
bromide (lpg/ml) for 5min and visualised on an ultraviolet transilluminator 
(UVP inc). Images were captured using a polaroid camera (Kodak). 
Comparative genomic hybridisation 
Nick Translation 
Nick translation of genomic DNA was performed using nick translation 
kit 
reagents (Vysis, UK). One microgram of genomic tumour 
DNA was mixed with 
(2.5pl) 0.2mM Spectrum Green, dUTP, (5pl) 0.1 mM dTTP, (10pl) 0.1 mM 
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dNTP, (5pl) IOx nick translation buffer, and made up to 40VI with nuclease free 
water. Ten microlitres of nick translation enzyme (DNAse I /DNA polymerase 1) 
was added. The mixture was incubated at 15'C for 2-3 hours, and the reaction 
terminated by denaturing at 70'C for 10 minutes. 
One hundred nanograms of probe was mixed with IpI of loading buffer and run 
on a 1% agarose gel alongside a 1Kb DNA ladder to determine probe size. The 
incubation time was adjusted to ensure a final product size of 300-3000 bp. 
Preparation of unsynchronised metaphase slides 
Whole blood from a healthy volunteer (0.4ml) was cultured in 10ml complete 
medium, and phytohaemagglutinin 0.1ml (Gibco BRL) for 72h at 37C. One 
microgram of Colcemid (Gibco BRL) was added, and after one hour at 370C cells 
were pelleted, the medium removed and resuspended in 5ml hypotonic solution 
(KCI 0.075M). After 15min at 37'C the potassium chloride was removed and cells 
fixed in 10ml of fixative (methanol: glacial acetic acid, ratio 3: 1). The fixative was 
changed three times before storing at -20'C. 
Metaphase spreads were prepared by carefully dropping a diluted cell 
suspension in fixative onto a clean wet slide. Excess cytoplasm was removed by 
adding I drop of fixative to the slide before allowing to air dry at room 
temperature. Slides with few chromosome overlaps were selected and stored at 
-200C before use. 
Probe preparation 
Working on ice, 500ng of Spectrum Green labelled tumour DNA was mixed with 
250ng of Spectrum Red labelled DNA (Vysis, UK). Twenty five micrograms of 
human Cot-I DNA was added to block repetitive DNA sequences. The probe 
was ethanol precipitatedwith3M sodium acetate and 100% ice cold ethanol, 
dried 
and resuspended in 3pl nuclease free water and 7pl CGH hybridisation 
buffer 
(Vysis, UK) - 
Metaphase slides were denatured in 70% formamide/2xSSC at 
73'C for 2-5 
minutes and dehydrated in ice cold ethanol (70%, 95%, 
100%). At the same time 
the DNA probe was denatured at 73'C for 5 minutes. 
The probe mix was placed 
on a dry slide and sealed under a cover slip with rubber cement, and 
hybridised 
78 
Chapter Two : AML in the elderly, St Bartholomew's Hospital (1969-1999) 
at 37'C for 72 hours. The slides were then washed by removing the coverslip and 
agitating in OAxSSC / 0.3% NP40 at 74'C for 2 minutes and 
NSSC/0.1% NP40 for 1 minute at room temperature. Following dehydration in 
an ethanol series (70%, 95%, and 100%), the slides were air dried before mounting 
in DAPI 11 counterstain (125ng/ml citifluor) under a large coverslip (24x5Omm). 
Image analysis 
Slides were visualised using a fluorescence microscope (Leica DMRXA) and 
digital images of metaphases were captured using filters specific for Spectrum 
Green, Spectrum Red and DAPI linked to a charge coupled device (CCD) camera. 
Images were processed using digital image software specific for CGH (Perceptive 
Scientific Instruments Inc, UK). Metaphases were selected on the basis of high 
intensity green and red signal. Those with uneven hybridisation signal, granular 
pattern or fluorescence spots were avoided. For complete analysis 5-10 
metaphases were fully analysed and the mean ratio profile of Spectrum Green to 
Spectrum Red calculated. Amplifications and deletions were determined by 
green/red fluorescence ratios of 1.25 and 0.75 respectively in accordance with 
imaging software algorithm. 
Fluorescence in situ hybridisation (FISH) 
Conventional FISH analysis was performed in cases where there was a 
discrepancy between G-banded analysis and CGH profiles. Briefly, for the 
evaluation of gain or loss of whole chromosomes, a centromeric probe 
for 
chromosome 7 and whole chromosome paint for the X chromosome 
(Oncor, 
Gaitersburg USA) were used. For interphase FISH, centromeric probes for 
chromosome 4 and 12 were used (Oncor, Gaithersburg USA). 
Hybridisation and 
post hybridisation washes were carried out according to the recommendations of 
the probe supplier. Fluorescence detection was carried out using a 
Leica DMRXA 
microscope fitted with appropriate filter sets, images were captured using 
Mac 
Probe software (Perceptive Scientific Instruments Inc, 
UK). 
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Results 
The CGH results for the fifteen patients included in the study are summarised in 
Table 3-3. CGH provided no additive information in the nine cases with normal 
karyotype by G-banded, which all had normal CGH profiles. Six patients 
included in the study had an abnormal karyotype by conventional G-banded 
analysis. CGH analysis revealed DNA copy number change in 5 of these cases 
(01,02,04,05,06). The remaining case, (03) had a balanced translocation, and had 
a normal CGH profile. Of the 5 cases with DNA copy number change, CGH was 
in complete concordance with karyotype data in 3 cases (01,02, and 05) (Figure 
3.2-3.4). In the remaining two cases (04,06) CGH analysis was discordant with G- 
banded karyotype. In case 06 CGH demonstrated monosomy 7 and trisomy 4 in 
4/8 metaphases captured, but the averaged profile for the 8 metaphases captured 
was not statistically significant as determined by the image analysis software. In 
the same case both trisomy 12 and 22 (noted in 60% of dividing cells by G- 
banded analysis), was not apparent by CGH analysis (Figure 3.5). CGH analysis 
of case 04 revealed a complete loss of chromosome 7, whilst G-banded analysis 
described a partial deletion, del(7)(q22q36). In order to elucidate the nature of the 
discrepancy, metaphase FISH was performed using a centromeric probe for 
chromosome 7. This confirmed monosomy 7 in six out of seven metaphase cells 
analysed, thus correlating with the CGH profile in this case (Figure 3-6). 
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Table 3-3 
Summary of the cytogenetic results from 15 elderly patients analysed by CGH 
Patient G-banded karyotype CGH-karyotype 
01 47, X, ictic(X)(ql2-13), +idic(X)(ql2-13) rev ish enh(Xp), dim(Xq) 
02 47, XY, +I, der(1; 7)(qlO; plO), rev ish enh(lq), dim(7q), enh(21q) 
inv(3)(q2lq26), +21 
03 46, XY, t(12; 17)(pl2; pl3) rev ish XY 
04 48, XX,? +X, del(7)(q22q36), rev ish dim(7), enh(21), 
+21/46, X, idic(X)(qll) /45, X, -X/46, XX enh(Xp), dim(Xq) 
05 45, XY, -7 rev ish dim(7), 
06* 45, XX, -7, add(8)(q24)/ rev ish enh(4), dim(7) 
48, idem, +4, +12, +12 
07 46, XX rev ish XX 
08 46, XY rev ish XY 
09 46, XX rev ish XX 
10 46, XX rev ish XX 
11 46, XY rev ish XY 
12 46, XX rev ish XX 
13 46, XX rev ish XX 
14 46, XX rev ish XX 
15 46, XX rev ish XX 
Key enh=enhanced (i. e. gain of that region) 
dim=diminished (i. e. loss of that region) 
*averaged CGH profile not statistically significant 
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Discussion 
This study demonstrated that archival bone marrow mononuclear cells can be 
successfully used as a source of DNA for CGH analysis in AML. Furthermore, 
the results of this study revealed a high level of concordance between CGH 
profiles and conventional banding analysis in the majority of patients studied. 
This second finding agrees with previous reported studies in which AML was 
analysed by CGH (Bentz et al., 1995a; Wilkens et al., 1998). Bone marrow blast 
counts were available in 8/9 patients with normal karyotype analysed by CGH, 
and averaged 85% (range 45-97%), indicating that DNA extraction was derived 
from a highly enriched population of leukaemic blasts in most cases. Thus it can 
be inferred that in some elderly patients with AML, leukaemic blasts have no 
evidence of DNA copy number change and have a normal karyotype. Normal 
CGH profiles have also been reported by others in cases of haematological 
malignancy with normal karyotype (Huhta et al., 1999; Wilkens et al., 1998). 
Therefore this suggests that cryptic DNA copy number change may not be a 
frequent event in patients with haematological malignancy characterised by a 
normal karyotype. 
The results of this study reveal other interesting aspects of CGH. Although CGH 
and G-banded analysis produced comparable results, the two techniques have 
fundamental methodological differences. Conventional cytogenetics results in the 
analysis of metaphase cells. However, the lineage of the haemopoietic cells 
undergoing mitosis may alter depending on the duration of culture (Keinanen et 
al., 1986). By comparison, CGH results in the analysis results of metaphase and 
interphase nuclei, which may include non-malignant cells like fibroblasts, or 
normal haernopoietic bone marrow mononuclear cells. This represents an 
advantage of CGH, but also a limitation. In case 06, CGH was unable to detect 
two numerical aberrations (trisomy 12 and 22), trisomy 12 was in found in a low 
percentage of interphase cells by interphase FISH, (29%). However, both 
aberrations were detected using conventional cytogenetic analysis. Thus G- 
banded analysis can detect small sub-clones with a high mitotic index, whilst 
chromosomal aberrations present in small subclones may be missed by CGH. 
Initial studies in which the resolving power of CGH was determined suggested 
that at least 50% of the studied population must carry the imbalance, and that the 
chromosomal region must be at least 2Mbp if a gain of genomic material 
is to be 
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detected, and at least 1OMbp for deleted material (Kallioniemi et al., 1994; Piper et 
al., 1995). In case 06 trisomy 12 was found in 29% of interphase nuclei, which is 
below the level of resolution of CGH reported by Kalioniemi. However, in a 
recent study of thirty eight cases of haematological malignancy with cytogenetic 
mosaicism, genomic imbalances could still be detected if the aberration was 
present when at least 23% of the cells analysed by CGH (Gebhart et al., 2000). 
Clearly the critical resolving power of CGH remains unknown but may be higher 
than originally thought. 
Several studies have shown CGH to be superior to conventional banding 
cytogenetics in the detection of numerical aberrations in leukaemia (Bentz et al., 
1995b; Karhu et al., 1997b; Larramendy et al., 1998a; Rice et al., 2000). In this study, 
the CGH profile of case 04 revealed a complete deletion of chromosome 7, whilst 
G-banded analysis suggested a partial deletion of 7q in 3 metaphases. FISH 
analysis of case 04 subsequently confirmed monosomy 7. Therefore it is likely 
that the del(7) was actually an idic(X) hence the revised karyotype of this clone 
would be: 46, X, idic(X)(qll)/45, idem, -7/46, idem, -7, +21. Thus CGH may detect 
certain numerical aberrations more effectively compared with conventional 
banding methods. However, in the cases included in this study, additive 
cytogenetic data was provided in only one case (04). Using MRC criteria 
(Grimwade et al., 1998), monosomy 7 is associated with poor prognosis whilst 7q- 
deletions predict for standard risk. Therefore the additive information provided 
by CGH in case 04 would have altered the prognostic significance of the 
presentation karyotype in this patient. 
Although CGH has the unique ability to screen the entire genome in a single 
hybridisation for DNA copy number change, the procedure is technically 
demanding. A significant number of experiments resulted in either poor 
hybridisation or no hybridisation at all. The factors most critical to the assay were 
found to be quality of genomic DNA and metaphase preparations. It was not 
possible to obtain CGH results from cases in which the concentration of 
high 
molecular weight DNA was low. Furthermore, although metaphase preparations 
selected for CGH appeared to have suitable morphology under phase contrast 
microscopy, in many cases the DAPI image revealed a 
C-banded chromosome 
image consistent with excessive denaturation, and resulted 
in poor hybridisation. 
Whilst in some experiments the DAPI image derived 
from the chromosomes was 
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poor resulting in incomplete karyotyping unsuccessful CGH analysis. The best 
results were achieved when metaphase preparations were allowed to *'age' at 
-20'C for 2 to 4 weeks prior to use. By doing so it was possible to denature 
chromosomes without incurring deterioration in chromosome architecture. 
Summary 
Evidence from this study confirms that CGH can be used in the successful 
cytogenetic study of AML, and in the elderly, produces a high level of 
concordance with conventional cytogenetic analysis. However, chromosomal 
aberrations involving small side clones may be missed. Importantly, the 
technique can be used to analyse cases for DNA copy number change using 
archival leukaemic blast cells as a source of genomic DNA. 
Comparative genomic hybridisation is technically demanding, and requires 
expensive hardware and software investment. The results obtained in this study 
indicate that the routine use of CGH in the cytogenetic analysis would add little 
to conventional banding analysis. However, CGH may prove useful in cases of 
AML where banding analysis is incomplete, due to poor chromosome 
morphology, complex karyotype, or in circumstances where conventional 
analysis fails completely. 
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Chapter 4 
Background 
Conventional cytogenetic techniques detect chromosomal aberrations in the 
majority of patients with AML. The clinical significance of this data in elderly 
patients with AML was illustrated in chapter 2. 
Conventional banding analysis is technically demanding, time consuming, and 
may be incomplete in cases with complex chromosomal rearrangements and or 
marker chromosomes. In the late 1980's new FISH protocols were developed 
which allowed the delineation of whole chromosomes and chromosomal 
subregions (Kearney, 1999). The increasing number of spectrally distinct 
fluorochromes that can be utilised for nucleic acid labelling has led to an increase 
in the number of DNA targets that can be visualised simultaneously. By utilising 
two different strategies namely combinatorial labelling and ratio labelling it is 
possible to identify or discriminate more DNA targets than the number of 
spectrally distinct fluorochromes available (Dauwerse et al., 1992; Nederlof et al., 
1990). 
Multiplex-FISH (M-FISH) is a new molecular cytogenetic technique which allows 
the simultaneous visualisation of each human chromosome in a specific colour in 
a single hybridisation (Speicher et al., 1996). Structural rearrangements are 
denoted by a change in colour along the length of the derivative chromosome. 
Multiplex-FISH, and a similar technique spectral karyotyping (SKY) (Schrock et 
al., 1996), can be used to detect simple or complex chromosomal translocations, as 
well as interstitial insertions. In addition, unlike conventional 
banding methods, 
M-FISH and SKY offer a high degree of automation 
in the analysis of 
chromosomal rearrangements (Eils et al., 1998). 
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Principles of 24 Colour FISH 
The M-FISH protocol relies upon the simultaneous hybridisation of specific 
whole chromosome DNA probes, labelled with a combination of fluorochromes, 
to the metaphase preparations of a sample to be analysed. Separate digital 
images of the metaphase preparation are captured for each fluorochrome using a 
CCD camera. The images are then analysed using dedicated software, which 
assigns a pseudo-colour to each chromosome, dictated by the fluorochrome 
composition of the DNA probes (Figure 4.1). 
In order to produce a probe mixture capable of identifying the 22 autosomes and 
2 sex chromosomes within the human genome, specific DNA probes for each 
chromosome (generated by micro-dissection or flow cytometry, and PCR 
amplification) are labelled by nick translation, in a combinatorial manner. The 
minimum number of fluorochromes required to achieve this is defined by the 
equation C=2 N_j' where C is the number of useful combinations, and N is the 
number of fluorochromes, thus when N=5, C=31. 
Spectral karyotyping like M-FISH utilises a mixture of whole chromosome DNA 
probes, labelled in a combinatorial manner, with fluorochromes to 'paint' 
metaphase preparations. The image is then captured and an interferometer is 
used to determine the spectrum of fluorescence wavelength for each pixel of the 
CCD chip. Identification of the components of this spectrum is achieved by 
dedicated software which applies an algorithm (Fourier transformation) in order 
to produce a pseudo-colour for each chromosome, resulting in a spectral 
karyotype (Schrock et al., 1996). 
The two methodologies have there own distinct advantages and 
disadvantages. 
Multiplex-FISH requires a series of image acquisitions for each 
fluorochrome. 
Thus although exposure times can be altered to compensate 
for weak 
fluorochrome signal, the final pseudo-colour image may 
be poor if any one 
fluorochrome signal is below threshold. Although 
SKY requires a single image 
acquisition, the exposure times are longer than 
in M-FISH, which may result in 
fluorochrome bleaching and an impaired pseudo-colour image 
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Multiplex-FISH and SKY studies in Haematological Malignancy 
Since the introduction of M-FISH and SKY in 1996 there have been a limited 
number of studies in which these techniques have been employed in the 
cytogenetic analysis of haernatological malignancy (Table 4-1). The largest series 
have been reported separately in patients with acute leukaemia and multiple 
myeloma. M-FISH was used to analyse 15 cases of haematological malignancy 
including 3 cases of AML and was able to identify marker chromosomes, and 
detect a number of cryptic translocations missed by G-banded analysis (Veldman 
et al., 1997). When SKY was used to analyse 32 cases of AML additive information 
was obtained in several cases with abnormal karyotype, but all patients with 
normal karyotype by G-banded analysis had normal karyotypes using SKY 
(Mohr et al., 2000). However, in a similar series 2/28 cases of AML with normal 
karyotype analysed using SKY were found to have cryptic aberrations (Zhang et 
al., 2000). 
In order to determine whether cryptic translocations were present in T-cell ALL 
analogous to the t(12; 21) in childhood B-ALL, SKY was utilised to analyse 15 
cases of T-ALL (Rowley et al., 1999). In 3 cases with complex karyotype, SKY was 
able to clarify the karyotypic aberrations by identifying unknown material 
present on a series of chromosomes. Concordance with conventional karyotype 
was noted in 11 other cases, whilst in the remaining case SKY was unable to 
detect a translocation present in a small clone of cells. When 24-colour FISH was 
used to analyse metaphase preparations from patients with multiple myeloma 
marker chromosomes and cryptic translocations were identified (Rao et al., 1998). 
The studies cited above clearly illustrate that M-FISH and SKY technologies 
assays can provide additive cytogenetic data in cases of haernatological 
malignancy, including cases with normal karyotype. 
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Table 4-1 Multicolour-FISH studies in haematological malignancy 
Study Disease Assay Com-ments 
Veldman AML, CML, MDS SKY marker chromosomes identified 
1997 ALL, NHL cryptic translocations identified 
Rao Myeloma, SKY marker chromosomes identified 
1998 Myeloma cell lines cryptic translocations identified 
Sawyer Myeloma SKY 156 aberrations resolved by 
1998 
Rowley T-ALL SKY karyotypes clarified in 3 cases 
1999 missed translocation in 1 case 
Tosi AML GF-D8 M-FISH M-FISH detected der(7)t(7,15) 
1999 cell line 
Gribble CML K562 M-FISH marker chromosome identified, 
2000 cell line CGH cryptic t(12; 21) identified, 
del(20q) identified 
Harrison CML(blast crisis) M-FISH concordant with G-banded 
2000 analysis 
Mohr AML/MDS SKY SKY detected cryptic aberrations 
2000 in 2 cases 
Wan T-lymphoblastic NHL SKY cryptic translocation identified 
2000 in a case with complex karyotype 
Zhang AML SKY SKY detectedcryptic aberrations 
2000 in 2/28 cases 
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Aims of this Study 
Acquired cytogenetic aberrations are detected in the majority of patients 1Nith 
AML using conventional banding techniques. Analysis of the presentation 
karyotype data from elderly patients with AML in chapter 2 revealed that 56% 
had abnormal karyotype. The majority of these patients, together with patients 
with normal karyotype were characterised by a clinical outcome intermediate 
between patients with 'favourable' and 'unfavourable' karyotype. Important 
cryptic chromosomal rearrangements may go undetected when using 
conventional banding techniques due to sub-optimal morphology, reduced 
mitotic index or due to the exchange of chromosomal material of similar contrast. 
In addition, whilst CGH can detect DNA copy number change, translocations go 
undetected. 
It is clear that cryptic aberrations of prognostic importance in cases of acute 
leukaemia with normal karyotype, as illustrated by the 12; 21 translocation in 
childhood leukaemia (Shurtleff et al., 1995). The aim of this study is to determine 
whether M-FISH can detect cryptic chromosomal rearrangements in elderly 
patients with AML with wither normal or abnormal karyotype., and to compare 
the cytogenetic data provided by M-FISH with the G-banded karyotype at the 
time of presentation, and determine the prognostic significance of any additive 
data provided by the technique. 
Patients and Methods 
Patients material 
Eighteen patients with AML (aged>60 years old) referred 
to the ICRF 
Department of Medical Oncology, St Bartholomew's 
Hospital and successfully 
karyotyped, with archival material suitable for analysis were selected 
for the 
study. Of these cases, five were also included 
in the previous CGH study (01,03, 
05,06,13). The clinical and laboratory data of the patients are 
listed in Table 4-2. 
Conventional cytogenetic analysis was performed as previously 
described at the 
time of diagnosis. 
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Table 4-2 
Clinical and laboratory details of AML patients included in the M-FISH study 
Case Age Year 
of diagnosis 
Sex FAB BM 
blast 
Karyotýpe 
01 71 1998 F mi 54 A 
03 60 1998 m M4 46 A 
05 71 1995 m mi 70 A 
06 60 1998 F M2 54 A 
13 68 1997 F M4 90 N 
16 74 1999 m M2 89 A 
17 79 1999 F mi 71 A 
18 74 1999 F M2 63 A 
19 60 1999 m M2 41 A 
20 77 1999 m M5 80 A 
21 74 1999 F M4 90 N 
22 68 1999 m M2 30 N 
23 78 2000 F M4 65 N 
24 71 1996 m M6 35 N 
25 64 1999 F M5 60 
N 
26 60 1999 m M2 62 
N 
27 76 1997 m M2 68 
N 
28 73 1999 m mi 89 
A 
Key A= abnormal karyotype 
N= normal karyotype 
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Multiplex Fluorescence in-situ Hybridisation 
Metaphase slide preparation 
Metaphase preparations from patients,, stored at -200C in fixative at the time of diagnosis were retrieved and resuspended in fresh fixative. Metaphase slides 
were then prepared as previously described. Slides with minimal cytoplasm were 
selected and air dried at 70'C for 2 hours, and then left overnight at room 
temperature before use. 
Probe preparation 
Metaphase slides were denatured at 73C for 2 minutes in 70% 
formamide/2xSSC dehydrated with ethanol (70%, 95%, and 100%) for 1 minute 
each and left to dry in air at room temperature. At the same time, 5PI of Spectra 
Vysion probe (Vysis, UK) was denatured for 5 minutes then applied to the 
denatured metaphase slide preparation. Hybridisation was performed at 37C for 
18 hours in a humidified light proof box. Slides were then washed by removing 
the coverslip and agitating in 0.4xSSC/0.3`/` NP40 (pH 7.0) at 74'C for 2 minutes 
and 2xSSC/0.1`/` NP40 (pH 7.0) for 30 seconds at room temperature. After 
drying, slides were mounted in 10pl DAPI III (42ng/ml) (Vysis UK) under 
(22x33mm) coverslip. 
Image Acquisition 
Metaphase images were captured using an Olympus AX70 fluorescence 
microscope (Olympus, UK) fitted with an M-FISH filter configuration (Vysis, 
UK), CCD camera. Image analysis was performed using Perceptive Scientific 
Instrument M-FISH'm software on an Apple Macintosh Power Mac computer. 
Five to ten metaphase cells were analysed for each patient, and aberrations were 
classified as clonal when detected in two or more metaphase cells (Mitelman, 
1995). 
Fluorescence in situ hybridisation (FISH) 
Conventional FISH analysis was performed in cases where there was a 
discrepancy between banding analysis and M-FISH karyotype. For the 
evaluation of cryptic translocations whole chromosome paints for chromosomes 
3,5,9,11,12,13,20,21 and centromeric probes for chromosome 8 and 17 were 
used (Oncor, Gaitersburg USA). Hybridisation and post hybridisation washes 
were carried out according to the recommendations of the supplier. 
Fluorescence 
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detection was carried out using a Leica DMXRA microscope fitted with 
appropriate filter sets, images were captured using digital image analysis 
software (Perceptive Scientific Instruments Inc, UK). 
Results 
Metaphase preparations from 18 patients (9 with abnormal karyotypes) were 
analysed by M-FISH, five of these patients were also analysed by CGH (01,03,05, 
06, and 13). A summary of the M-FISH results together with conventional 
cytogenetic data is shown in Table 4-3. The G-banded analysis of case 06 showed 
additional material on chromosome 8. M-FISH analysis identified the origin of 
the extra material as being derived from chromosome 3. In addition, M-FISH 
suggested the presence of a cryptic t(3; 11) translocation in 3/7 cells analysed. 
FISH analysis with whole chromosome paints for chromosomes 3,8, and 11, 
confirmed the presence of the t(3; 8) translocation, but the t(3; 11) translocation 
could not be demonstrated (Figure 4.2). 
G-banded analysis demonstrated a balanced t(12; 17)(p12; p13) translocation in 
case 03. However, M-FISH failed to demonstrate this telomeric rearrangement in 
the metaphase preparations captured. FISH analysis (on metaphase 
chromosomes from the same sample) using probes for chromosomes 12 and 17 
clearly demonstrated the presence of this translocation (Figure 4.3). 
A complex pattern of chromosomal abnormalities was noted in case 028 by G- 
banded analysis, which included a marker chromosome, and additional material 
of unknown origin on chromosomes 9,16 and 21. M-FISH revealed a 
rearrangement between chromosome 5,9 and 21. There was also an abnormal 
chromosome 13 containing a homogenously staining region (hsr) derived 
from 
chromosome 11. This hsr was translocated to chromosome 16 in a sideline clone. 
FISH analysis using whole chromosome paints for chromosome 
5,9,13,17 and 
21 confirmed these rearrangements (Figure 4.4). 
M-FISH karyotypes were concordant with the G-banded analysis in the 
remaining 16 patients, M-FISH revealed a shortened chromosome 
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consistent with i(7)(pIO), and demonstrated an abnormal X chromosome 
consistent with idic(X) in case 01. Metaphase cells from nine patients with a 
normal karyotype had a normal karyotype when analysed using M-FISH. An 
average of 6 cells per patient was analysed in these cases. Despite this relatively 
small number, the bone marrow samples from the majority of these patients 
contained more than 60% blasts. Thus the leukaernic blasts of some patients may 
have a normal karyotype. 
Discussion 
M-FISH is an important FISH based molecular cytogenetic technique which 
makes the identification of marker chromosomes, and the complete analysis of 
complex karyotypes in haematological malignancy possible (Tosi et al., 1999; 
Veldman et al., 1997). In this study M-FISH clarified the chromosomal 
abnormalities of two patients with complex karyotype. In both cases, standard G- 
banded analysis identified chromosomes that had additional unidentified 
material. M-FISH was able to identify the origin of this material as well as the 
origin of a homogenously staining region in one case. In one other case a 
balanced telomeric translocation identified by G-banded was not detected by M- 
FISH, but was detected with FISH using centromeric probes. M-FISH was 
concordant with G-banded analysis in 7 cases that had numerical aberrations, 
and or balanced translocation. Importantly, no recurring cryptic aberrations were 
found in patients with normal or abnormal karyotype. 
The ability of M-FISH to detect chromosomal translocations is dependent upon 
the location of the chromosomal aberration, quality of the metaphase 
preparations, and the size of the chromosomal rearrangement. Multiplex-FISH 
analysis of case 03 clearly illustrated that M-FISH was unable to detect the 
presence of a telomeric rearrangement. Similarly, subtelomeric translocations in 
multiple myeloma involving segment 14q32 were too small to 
be resolved 
completely by SKY (Sawyer et al., 1998). The inability to consistently 
detect 
subtelomeric rearrangements using M-FISH or SKY may 
be improved by 
increasing the relative proportion of telomeric/subtelomeric DNA within the 
probe mixture (Kearney, 1999; Zhang et al., 2000). 
Likewise, bý, spiking the probe 
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mixture with band probes spanning known translocation breakpoints, may allow 
M-FISH to target specific chromosomal breakpoints associated with AML or 
other haematological malignancies (Speicher et al., 1996). 
High quality metaphase preparations are essential for accurate M-FISH analysis. 
Metaphase preparations in this study were prepared from archival material 
stored in fixative at the time of diagnosis. Although successful M-FISH analysis 
was possible using this material as a source, it also resulted in some technical 
difficulties. For example, the chromosomes of a number of metaphase 
preparations from samples more than 1 year old were frequently of poor quality, 
or the metaphase preparations themselves were scanty or had abundant 
cytoplasm. This resulted in suboptimal analysis in a number of cases, and made 
it impossible to analyse the metaphase preparations from several patients 
included in the CGH study. In the cases in which M-FISH and CGH were both 
utilised, M-FISH identified the numerical aberrations detected by CGH, as well 
the origin of chromosomal material involved in a translocation (case 06). Thus 
although M-FISH and CGH have their own distinct advantages pertaining to 
cytogenetic analysis, it can be argued that M-FISH provided a more 
comprehensive assessment of presentation karyotype than CGH. 
As outlined in the previous chapters, cytogenetic data provided at the time of 
diagnosis may influence the management of young and middle aged AML 
patients by virtue of its prognostic power (Bloomfield et al., 1984; Grimwade et 
al., 1998). Likewise, karyotype at the time of diagnosis in patients 60 years or 
older also carries prognostic significance, predicting for complete remission and 
overall survival (Dalley et al., 1999; Leith et al., 1997). Published 
data indicate that 
M-FISH has the ability to detect chromosomal rearrangements with a resolution 
between 5OOkb to I. OMb whereas banding techniques have a resolution 
equivalent to the size of a single band (5-IOMb). 
Despite this apparent 
superiority, M-FISH analysis failed to provide additive 
information in the 
majority of patients included in this study. 
Similar findings were noted when 
SKY was used to analyse patients with T-ALL and 
AML, suggesting that some 
blast cells in acute leukaemia may have a normal 
karyotype (Mohr et al., 2000; 
Rowley et al., 1999). However, in a recent study 
in which SKY was used to 
analyse 28 cases of AML with normal 
karyotype, 2 cases with normal karyotype 
were found to have cryptic aberrations 
(Zhang et al., 2000). The disparity between 
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these results may reflect sample size, as only 8 patients with normal karyotype 
were included in this study and an average of 5-10 cells per patient were 
analysed, whilst Zhang et al analysed 20 cells per patient. In addition the 
possibility remains that M-FISH may have missed abnormal clones in the 
patients analysed due to a low mitotic index. Multiplex-FISH was able to provide 
additive cytogenetic data in 2 cases where G-banded analysis was incomplete. 
However, in both these cases the banded karyotypes were complex and therefore 
associated with unfavourable outcome (Grimwade et al., 1998). Thus the additive 
cytogenetic data provided by M-FISH for these cases would not have changed 
the prognostic significance of the presentation karyotype of these patients had M- 
FISH been used alongside banding analysis at the time of diagnosis. In contrast, 
the study in which SKY detected cryptic aberrations in 2 cases of AML with 
normal karyotype resulted, in a change in the prognostic subgroup (Zhang et al., 
2000). 
Multiplex-FISH requires significant financial investment in product hardware, 
software and consumables. Although there was good overall concordance 
between M-FISH and G-banded analysis in this study, it is already clear that in 
cases where G-banded and M-FISH analysis are discordant, conventional FISH 
analysis should be used to confirm the results. Furthermore, given the technical 
limitations of M-FISH as demonstrated in this study, the need for further 
validation studies in which the clinical utility and diagnostic accuracy of WISH 
can be determined are required. Such studies will be mandatory if WISH is to 
move from being a research tool, to a vital diagnostic technique in clinical 
cytogenetics. 
Summary 
Multiplex-FISH is a new molecular cytogenetic technique that can identify 
marker chromosomes, and fully characterise complex karyotypes 
in patients with 
AML. This study illustrated that the technique could be successfully applied 
to 
archival metaphase preparations, and illustrated its potential 
diagnostic and 
clinical utility in elderly patients with AML, particularly 
those with complex 
chromosomal rearrangements. Based upon the 
findings in this study, there is 
little to currently recommend the routine use of 
M-FISH in the cytogenetic 
106 
Chapter Four: Multiplex-Fluorescence in-situ Hybridisation 
analysis of AML, as the additive cytogenetic data provided by the technique is 
marginal and unlikely to influence patient prognosis. However, other studies in 
which 24-colour FISH has been used to analyse AML cases have resulted in 
important prognostic cytogenetic data been uncovered in cases with normal 
karyotype. Modifications to M-FISH probe composition and analysis software 
may improve the sensitivity and resolving power of the assay. 
It is clear that M-FISH and SKY have the potential to augment conventional 
cytogenetic analysis and FISH for resolving karyotypes in AML. However, 
further validation studies are warranted before the true diagnostic and clinical 




It is clear from the results presented in chapter 2, and from published studies 
elsewhere that curative treatment strategies often result in poor clinical outcome 
for the majority of older patients with AML. With current intensive induction 
therapy and supportive care it is possible to achieve complete remission of the 
order of 40-50% in selected elderly patients, and if patients not selected for 
treatment are considered then in reality less than one third of elderly patients 
referred for treatment will achieve remission. Although these results are 
disappointing it is clear that improvements in the delivery of supportive care, 
and the introduction of more intensive curative regimens have considerably 
improved clinical outcome for older patients with AML. The dramatic reduction 
in treatment-related deaths documented in elderly patients with AML over three 
decades was undoubtedly as a result of improved supportive care, which also 
indirectly accounted for an increase in resistant disease as more patient with 
resistant disease were able to survive induction therapy. Similarly, the 
improvement in complete remission rates from 13% to 45% was probably a 
consequence of more intensive therapy and a greater ability to manage the 
complications associated with such treatment. 
Despite the poor outcome associated with elderly patients with AML it is clear 
that by using prognostic data, older patients with a better than average clinical 
outcome can be identified. For example, patients with "favourable" karyotype had 
a significantly better complete remission rate compared to patients with 
'unfavourable' karyotypes whilst younger age and the absence of 
hepatosplenomegaly were also associated with improved complete remission. 
When elderly patients with AML present with these clinical and biological 
characteristics, the decision to offer treatment with curative intent is relatively 
straightforward. However, cytogenetic aberrations predictive of "favourable' 
outcome occur infrequently in older patients, who commonly present with 
chromosomal aberrations predictive of intermediate orunfavourable' outcome. 
Furthermore the results from this study demonstrated that 'unfavourable" 
karyotypes were independent predictor of 
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reduced overall survival. Indeed when treated with curative intent, elderly 
patients with 'unfavourable' karyotype had a median survival of 4 weeks, which 
was identical to that of patients managed conservatively. Thus in the absence of 
experimental therapies the argument for managing patients with 'unfavourable" 
karyotype conservatively is compelling. It therefore seems clear that those co- 
variates which impact on clinical outcome in older patients with AML should be 
actively utilised in the therapeutic decision making process. Indeed several 
authors have advocated the use of prognostic scoring systems or prognostic data 
in order to facilitate the therapeutic decision making when managing elderly 
patients with AML (Estey, 2000b; Ferrara et al., 1998a; Johnson et al., 1995). One 
can argue that in older patients curative therapy should await the results of 
conventional cytogenetic analysis, which normally takes at least 48 hours, this 
delay would not be improved by implementing M-FISH or CGH technologies 
which currently require a minimum of 24 and 72 hours, excluding time for 
analysis. With this in mind the prognostic significance of serum LDH in 
predicting complete remission and survival is clear given the short turn around 
time associated with the test. Any future clinical studies in elderly AML patients 
should hopefully include the development and validation of a prognostic scoring 
system incorporating the prognostic co-variates identified in this study. 
It was hoped that additional cytogenetic data would be uncovered by the use of 
CGH and M-FISH in elderly patients with AML. Although it was possible to 
perform CGH using appropriately stored archival material the results obtained 
in this study suggest that there would be no advantage in the routine use of CGH 
in the analysis of AML. The technique was technically demanding, time 
consuming and would require stringent quality control with regard to metaphase 
preparations, tumour and reference DNA, as well as the routine use of 
appropriate controls. Although DNA copy number change was consistent with 
banding analysis in the majority of cases, there was a paucity of additive 
cytogenetic data. However, new developments namely cDNA microarray 
based 
CGH, offer the detection of genome wide DNA copy number change at a 
higher 
resolution than is currently possible with conventional 
CGH (Pinkel et al., 1998). 
In addition, it is also possible to profile gene expression with 
this new technology 
(Pollack et al., 1999). Although in its infancy microarray 
technology may allow 
the detection of dysregulated genes 
in AML, particularly in patients with normal 
karyotype. Preliminary results 
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suggest that it is already possible to distinguish between AML and ALL on the 
basis of gene expression profiling alone (Golub, 1999). It therefore follows that 
gene expression profiling may offer another way in which genetic data can be 
interpreted for prognostic purposes. 
It was possible to achieve a more comprehensive assessment of cytogenetic 
aberrations in elderly patients with AML through the use of M-FISH than with 
CGH. Importantly, the technique was relatively time efficient, requiring 18 hours 
for hybridisation. Furthermore it was also clear that M-FISH can provide additive 
cytogenetic data in cases with complex karyotype, provided that metaphase 
preparations of reasonable quality are available. However although WISH is a 
powerful technique it also has technical limitations, in that telomeric 
rearrangements may be missed as current commercially available probes contain 
relatively little PCR product from these regions. In addition it is not possible to 
detect inversion rearrangements with M-FISH. Based upon the results presented 
it would seem that the routine use of M-FISH in AML is unlikely to provide 
results that will alter the prognostic impact of cytogenetic data obtained with 
conventional banding analysis. Thus the acquisition and use of this technique, 
with regard to AML, is limited to the more accurate description of complex 
rearrangements by the cytogeneticist. Furthermore, given the limitations of M- 
FISH its use as a research tool in screening for cryptic aberrations in AML, 
particularly in those patients with normal karyotype, can not yet be 
recommended. 
Although the objective selection of older patients with AML for curative therapy 
is essential, it is important to emphasise that current curative therapies only 
benefit a minority of patients. Furthermore, if patients ineligible 
for curative 
therapy are considered then the necessity for experimental curative regimens, 
and innovative supportive care strategies is even more 
immediate. Severe 
infection, particularly during the period of bone marrow aplasia, was 
identified 
as the major cause of early death amongst patients receiving curative 
therapy. 
Thus interventions aimed at reducing infection in these patients would 
be 
advantageous. One author has advocated the use of parenteral 
antifungal 
therapy, and or granulocyte transfusions in 
febrile, in order to reduce the incidence of 
fungal pneumonia, although there is 
no obvious data to support these interventions 
(Estey, 2000b). The introduction of 
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novel therapeutic agents with less myelosuppressive activity than current 
curative regimens would seem to offer another approach to reducing early deaths. Calichearnicin is a cytotoxic antibiotic that induces double stranded DNA 
breaks when introduced into cells. When conjugated to humanised anti-CD33 
monoclonal antibody, and administered to patients with refractory AML, a CR 
rate of 13% and overall response rate of 43% has been documented (Sievers et al., 
1998). Importantly, patients who received this therapy in phase 11 trials 
experienced less toxicity than would be expected through the use of conventional 
therapy. Common side effects reported included fever, asymptomatic 
hypotension, nausea, vomiting and leucopenia. And in contrast to conventional 
curative therapy, there was an absence of mucositis and alopecia in those patients 
who received the monoclonal antibody. Thus by using this agent first line, it may 
be possible to offer curative therapy to elderly patients in whom conventional 
regimens would be contraindicated. Furthermore, it may be possible to avoid the 
significant morbidity associated with the delivery of consolidation chemotherapy 
by using this agent in those patients who achieve CR and are too frail to receive 
further conventional therapy. Thus the results of phase III trials in which anti- 
CD33/Calicheamicin conjugate is evaluated, should be eagerly awaited. 
The chimeric proteins that result from non-random chromosomal translocations 
may repress gene expression by recruiting histone-deacetylase (HDAQ to 
DNA/chromatin structures. The enzyme reduces the accessibility of transcription 
factors to DNA by removing acetyl groups from lysine residues on histones, 
leading to a closer association between DNA and histone complexes. The 
butyrates are a group of drugs that inhibit HDAC, and have been shown to 
induce remissions in patients with refractory AML (Zwiebel, 2000). The 
development of these drugs may lead to novel therapies for AML devoid of 
significant myelotoxicity, which would clearly be an advantage to older patients. 
Other drugs with novel activities include decitabine which promotes DNA 
demethylation when used with HDAC inhibitors. Decitabine acts synergisticaly to 
promote the re-expression of repressed genes silenced by chromosomal 
rearrangements (Estey, 2000b; Singal & Ginder, 1999). Therapeutic interventions 
aimed at modulating multi-drug resistance in older patients with AML 
have been 
evaluated in clinical trials. Unfortunately the promising results obtained with the 
cyclosporin analogue PSC833 in early phase I and 11 trials 
have not been repeated 
in phase III trials involving elderly patients (Stone, 1999). 
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In summary, an improvement in supportive care and the introduction of 
intensive chemotherapy has led to a significant improvement in clinical outcome 
for elderly patients treated with curative intent. Prognostic factors such as serum 
LDH, presentation karyotype and age can be used to objectively select elderly 
patients most likely to benefit from intensive chemotherapy. Comparative 
genomic hybridisation and M-FISH can be utilised in the cytogenetic analysis of 
AML. However, the additive cytogenetic data provided by these two techniques 
is limited, and can not justify their routine use in elderly AML. 
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